Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects
Identifieur interne : 000375 ( Ncbi/Merge ); précédent : 000374; suivant : 000376Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects
Auteurs : Anne Bonnet [France] ; Marie Jutras [France] ; Virginie Czernecki [France] ; Jean Corvol [France] ; Marie Vidailhet [France]Source :
- Parkinson's Disease [ 2090-8083 ] ; 2012.
Abstract
Nonmotor symptoms (NMSs) of Parkinson's disease (PD) are common, but they are often underrecognized in clinical practice, because of the lack of spontaneous complaints by the patients, and partly because of the absence of systematic questioning by the consulting physician. However, valid specific instruments for identification and assessment of these symptoms are available in 2012. The administration of the self-completed screening tool, NMSQuest, associated with questioning during the consultation, improves the diagnosis of NMSs. NMSs play a large role in degradation of quality of life. More relevant NMSs are described in this review, mood disorders, impulse control disorders, cognitive deficits, hallucinations, pain, sleep disorders, and dysautonomia.
Url:
DOI: 10.1155/2012/198316
PubMed: 22888466
PubMed Central: 3410355
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000328
- to stream Pmc, to step Curation: 000328
- to stream Pmc, to step Checkpoint: 000100
Links to Exploration step
PMC:3410355Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects</title><author><name sortKey="Bonnet, Anne Marie" sort="Bonnet, Anne Marie" uniqKey="Bonnet A" first="Anne" last="Bonnet">Anne Bonnet</name><affiliation wicri:level="1"><nlm:aff id="I1">APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I3">INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Jutras, Marie France" sort="Jutras, Marie France" uniqKey="Jutras M" first="Marie" last="Jutras">Marie Jutras</name><affiliation wicri:level="1"><nlm:aff id="I1">APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Czernecki, Virginie" sort="Czernecki, Virginie" uniqKey="Czernecki V" first="Virginie" last="Czernecki">Virginie Czernecki</name><affiliation wicri:level="1"><nlm:aff id="I1">APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I3">INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean" last="Corvol">Jean Corvol</name><affiliation wicri:level="1"><nlm:aff id="I1">APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I3">INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name><affiliation wicri:level="1"><nlm:aff id="I1">APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I3">INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22888466</idno><idno type="pmc">3410355</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410355</idno><idno type="RBID">PMC:3410355</idno><idno type="doi">10.1155/2012/198316</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000328</idno><idno type="wicri:Area/Pmc/Curation">000328</idno><idno type="wicri:Area/Pmc/Checkpoint">000100</idno><idno type="wicri:Area/Ncbi/Merge">000375</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects</title><author><name sortKey="Bonnet, Anne Marie" sort="Bonnet, Anne Marie" uniqKey="Bonnet A" first="Anne" last="Bonnet">Anne Bonnet</name><affiliation wicri:level="1"><nlm:aff id="I1">APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I3">INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Jutras, Marie France" sort="Jutras, Marie France" uniqKey="Jutras M" first="Marie" last="Jutras">Marie Jutras</name><affiliation wicri:level="1"><nlm:aff id="I1">APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Czernecki, Virginie" sort="Czernecki, Virginie" uniqKey="Czernecki V" first="Virginie" last="Czernecki">Virginie Czernecki</name><affiliation wicri:level="1"><nlm:aff id="I1">APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I3">INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean" last="Corvol">Jean Corvol</name><affiliation wicri:level="1"><nlm:aff id="I1">APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I3">INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name><affiliation wicri:level="1"><nlm:aff id="I1">APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I3">INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Parkinson's Disease</title><idno type="ISSN">2090-8083</idno><idno type="e-ISSN">2042-0080</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Nonmotor symptoms (NMSs) of Parkinson's disease (PD) are common, but they are often underrecognized in clinical practice, because of the lack of spontaneous complaints by the patients, and partly because of the absence of systematic questioning by the consulting physician. However, valid specific instruments for identification and assessment of these symptoms are available in 2012. The administration of the self-completed screening tool, NMSQuest, associated with questioning during the consultation, improves the diagnosis of NMSs. NMSs play a large role in degradation of quality of life. More relevant NMSs are described in this review, mood disorders, impulse control disorders, cognitive deficits, hallucinations, pain, sleep disorders, and dysautonomia.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Chaudhuri, Kr" uniqKey="Chaudhuri K">KR Chaudhuri</name></author><author><name sortKey="Healy, D" uniqKey="Healy D">D Healy</name></author><author><name sortKey="Shapira, Ahv" uniqKey="Shapira A">AHV Shapira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author><author><name sortKey="Rodriguez Blazquez, C" uniqKey="Rodriguez Blazquez C">C Rodriguez-Blazquez</name></author><author><name sortKey="Abe, K" uniqKey="Abe K">K Abe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaudhuri, Kr" uniqKey="Chaudhuri K">KR Chaudhuri</name></author><author><name sortKey="Odin, P" uniqKey="Odin P">P Odin</name></author><author><name sortKey="Antonini, A" uniqKey="Antonini A">A Antonini</name></author><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grosset, D" uniqKey="Grosset D">D Grosset</name></author><author><name sortKey="Taurah, L" uniqKey="Taurah L">L Taurah</name></author><author><name sortKey="Burn, Dj" uniqKey="Burn D">DJ Burn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tolosa, E" uniqKey="Tolosa E">E Tolosa</name></author><author><name sortKey="Gaig, C" uniqKey="Gaig C">C Gaig</name></author><author><name sortKey="Santamaria, J" uniqKey="Santamaria J">J Santamaría</name></author><author><name sortKey="Compta, Y" uniqKey="Compta Y">Y Compta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Witjas, T" uniqKey="Witjas T">T Witjas</name></author><author><name sortKey="Kaphan, E" uniqKey="Kaphan E">E Kaphan</name></author><author><name sortKey="Azulay, Jp" uniqKey="Azulay J">JP Azulay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barone, P" uniqKey="Barone P">P Barone</name></author><author><name sortKey="Antonini, A" uniqKey="Antonini A">A Antonini</name></author><author><name sortKey="Colosimo, C" uniqKey="Colosimo C">C Colosimo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Ullivan, Ss" uniqKey="O Ullivan S">SS O’Sullivan</name></author><author><name sortKey="Williams, Dr" uniqKey="Williams D">DR Williams</name></author><author><name sortKey="Gallagher, Da" uniqKey="Gallagher D">DA Gallagher</name></author><author><name sortKey="Massey, La" uniqKey="Massey L">LA Massey</name></author><author><name sortKey="Silveira Moriyama, L" uniqKey="Silveira Moriyama L">L Silveira-Moriyama</name></author><author><name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shulman, Lm" uniqKey="Shulman L">LM Shulman</name></author><author><name sortKey="Taback, Rl" uniqKey="Taback R">RL Taback</name></author><author><name sortKey="Bean, J" uniqKey="Bean J">J Bean</name></author><author><name sortKey="Weiner, Wj" uniqKey="Weiner W">WJ Weiner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author><author><name sortKey="Shapira, Ahv" uniqKey="Shapira A">AHV Shapira</name></author><author><name sortKey="Stocchi, F" uniqKey="Stocchi F">F Stocchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wolters, Ec" uniqKey="Wolters E">EC Wolters</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Remy, P" uniqKey="Remy P">P Remy</name></author><author><name sortKey="Doder, M" uniqKey="Doder M">M Doder</name></author><author><name sortKey="Lees, A" uniqKey="Lees A">A Lees</name></author><author><name sortKey="Turjanski, N" uniqKey="Turjanski N">N Turjanski</name></author><author><name sortKey="Brooks, D" uniqKey="Brooks D">D Brooks</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaudhuri, Kr" uniqKey="Chaudhuri K">KR Chaudhuri</name></author><author><name sortKey="Schapira, Ah" uniqKey="Schapira A">AH Schapira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thobois, S" uniqKey="Thobois S">S Thobois</name></author><author><name sortKey="Ardouin, C" uniqKey="Ardouin C">C Ardouin</name></author><author><name sortKey="Schmitt, E" uniqKey="Schmitt E">E Schmitt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Voon, V" uniqKey="Voon V">V Voon</name></author><author><name sortKey="Fernagut, Po" uniqKey="Fernagut P">PO Fernagut</name></author><author><name sortKey="Wickens, J" uniqKey="Wickens J">J Wickens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schrag, A" uniqKey="Schrag A">A Schrag</name></author><author><name sortKey="Jahanshahi, M" uniqKey="Jahanshahi M">M Jahanshahi</name></author><author><name sortKey="Quinn, N" uniqKey="Quinn N">N Quinn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaudhuri, Kr" uniqKey="Chaudhuri K">KR Chaudhuri</name></author><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author><author><name sortKey="Brown, Rg" uniqKey="Brown R">RG Brown</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author><author><name sortKey="Rodriguez Blazquez, C" uniqKey="Rodriguez Blazquez C">C Rodriguez-Blazquez</name></author><author><name sortKey="Kurtis, Mm" uniqKey="Kurtis M">MM Kurtis</name></author><author><name sortKey="Chaudhuri, Kr" uniqKey="Chaudhuri K">KR Chaudhuri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Seppi, K" uniqKey="Seppi K">K Seppi</name></author><author><name sortKey="Weintraub, D" uniqKey="Weintraub D">D Weintraub</name></author><author><name sortKey="Coelho, M" uniqKey="Coelho M">M Coelho</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tom, T" uniqKey="Tom T">T Tom</name></author><author><name sortKey="Cummings, Jl" uniqKey="Cummings J">JL Cummings</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ravina, B" uniqKey="Ravina B">B Ravina</name></author><author><name sortKey="Camicioli, R" uniqKey="Camicioli R">R Camicioli</name></author><author><name sortKey="Como, Pg" uniqKey="Como P">PG Como</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cummings, Jl" uniqKey="Cummings J">JL Cummings</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reijnders, Jsam" uniqKey="Reijnders J">JSAM Reijnders</name></author><author><name sortKey="Ehrt, U" uniqKey="Ehrt U">U Ehrt</name></author><author><name sortKey="Weber, Wej" uniqKey="Weber W">WEJ Weber</name></author><author><name sortKey="Aarsland, D" uniqKey="Aarsland D">D Aarsland</name></author><author><name sortKey="Leentjens, Afg" uniqKey="Leentjens A">AFG Leentjens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tan, Lcs" uniqKey="Tan L">LCS Tan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Devos, D" uniqKey="Devos D">D Devos</name></author><author><name sortKey="Dujardin, K" uniqKey="Dujardin K">K Dujardin</name></author><author><name sortKey="Poirot, I" uniqKey="Poirot I">I Poirot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Menza, M" uniqKey="Menza M">M Menza</name></author><author><name sortKey="Dobkin, Rd" uniqKey="Dobkin R">RD Dobkin</name></author><author><name sortKey="Marin, H" uniqKey="Marin H">H Marin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dobkin, Rd" uniqKey="Dobkin R">RD Dobkin</name></author><author><name sortKey="Menza, M" uniqKey="Menza M">M Menza</name></author><author><name sortKey="Bienfait, Kl" uniqKey="Bienfait K">KL Bienfait</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marsh, L" uniqKey="Marsh L">L Marsh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nuti, A" uniqKey="Nuti A">A Nuti</name></author><author><name sortKey="Ceravolo, R" uniqKey="Ceravolo R">R Ceravolo</name></author><author><name sortKey="Piccini, A" uniqKey="Piccini A">A Piccini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leentjens, Af" uniqKey="Leentjens A">AF Leentjens</name></author><author><name sortKey="Dujardin, K" uniqKey="Dujardin K">K Dujardin</name></author><author><name sortKey="Marsh, L" uniqKey="Marsh L">L Marsh</name></author><author><name sortKey="Richard, Ih" uniqKey="Richard I">IH Richard</name></author><author><name sortKey="Starkstein, Se" uniqKey="Starkstein S">SE Starkstein</name></author><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leentjens, Afg" uniqKey="Leentjens A">AFG Leentjens</name></author><author><name sortKey="Dujardin, K" uniqKey="Dujardin K">K Dujardin</name></author><author><name sortKey="Marsh, L" uniqKey="Marsh L">L Marsh</name></author><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author><author><name sortKey="Richard, Ih" uniqKey="Richard I">IH Richard</name></author><author><name sortKey="Starkstein, Se" uniqKey="Starkstein S">SE Starkstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Belzer, K" uniqKey="Belzer K">K Belzer</name></author><author><name sortKey="Schneier, Fr" uniqKey="Schneier F">FR Schneier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brown, Rg" uniqKey="Brown R">RG Brown</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olanow, Cw" uniqKey="Olanow C">CW Olanow</name></author><author><name sortKey="Stern, Mb" uniqKey="Stern M">MB Stern</name></author><author><name sortKey="Sethi, K" uniqKey="Sethi K">K Sethi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marin, Rs" uniqKey="Marin R">RS Marin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Starkstein, Se" uniqKey="Starkstein S">SE Starkstein</name></author><author><name sortKey="Leentjens, Afg" uniqKey="Leentjens A">AFG Leentjens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Starkstein, Se" uniqKey="Starkstein S">SE Starkstein</name></author><author><name sortKey="Mayberg, Hs" uniqKey="Mayberg H">HS Mayberg</name></author><author><name sortKey="Preziosi, Tj" uniqKey="Preziosi T">TJ Preziosi</name></author><author><name sortKey="Andrezejewski, P" uniqKey="Andrezejewski P">P Andrezejewski</name></author><author><name sortKey="Leiguarda, R" uniqKey="Leiguarda R">R Leiguarda</name></author><author><name sortKey="Robinson, Rg" uniqKey="Robinson R">RG Robinson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sockeel, P" uniqKey="Sockeel P">P Sockeel</name></author><author><name sortKey="Dujardin, K" uniqKey="Dujardin K">K Dujardin</name></author><author><name sortKey="Devos, D" uniqKey="Devos D">D Devos</name></author><author><name sortKey="Deneve, C" uniqKey="Deneve C">C Denève</name></author><author><name sortKey="Destee, A" uniqKey="Destee A">A Destée</name></author><author><name sortKey="Defebvre, L" uniqKey="Defebvre L">L Defebvre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benito Le N, J" uniqKey="Benito Le N J">J Benito-León</name></author><author><name sortKey="Cubo, E" uniqKey="Cubo E">E Cubo</name></author><author><name sortKey="Coronell, C" uniqKey="Coronell C">C Coronell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levy, R" uniqKey="Levy R">R Levy</name></author><author><name sortKey="Dubois, B" uniqKey="Dubois B">B Dubois</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kirsch Darrow, L" uniqKey="Kirsch Darrow L">L Kirsch-Darrow</name></author><author><name sortKey="Fernandez, Hf" uniqKey="Fernandez H">HF Fernandez</name></author><author><name sortKey="Marsiske, M" uniqKey="Marsiske M">M Marsiske</name></author><author><name sortKey="Okun, Ms" uniqKey="Okun M">MS Okun</name></author><author><name sortKey="Bowers, D" uniqKey="Bowers D">D Bowers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thobois, S" uniqKey="Thobois S">S Thobois</name></author><author><name sortKey="Ardouin, C" uniqKey="Ardouin C">C Ardouin</name></author><author><name sortKey="Lhommee, E" uniqKey="Lhommee E">E Lhommée</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Czernecki, V" uniqKey="Czernecki V">V Czernecki</name></author><author><name sortKey="Pillon, B" uniqKey="Pillon B">B Pillon</name></author><author><name sortKey="Houeto, Jl" uniqKey="Houeto J">JL Houeto</name></author><author><name sortKey="Pochon, Jb" uniqKey="Pochon J">JB Pochon</name></author><author><name sortKey="Levy, R" uniqKey="Levy R">R Levy</name></author><author><name sortKey="Dubois, B" uniqKey="Dubois B">B Dubois</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Czernecki, V" uniqKey="Czernecki V">V Czernecki</name></author><author><name sortKey="Schupbach, M" uniqKey="Schupbach M">M Schüpbach</name></author><author><name sortKey="Yaici, S" uniqKey="Yaici S">S Yaici</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marin, Rs" uniqKey="Marin R">RS Marin</name></author><author><name sortKey="Fogel, Bs" uniqKey="Fogel B">BS Fogel</name></author><author><name sortKey="Hawkins, J" uniqKey="Hawkins J">J Hawkins</name></author><author><name sortKey="Duffy, J" uniqKey="Duffy J">J Duffy</name></author><author><name sortKey="Krupp, B" uniqKey="Krupp B">B Krupp</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weintraub, D" uniqKey="Weintraub D">D Weintraub</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weintraub, D" uniqKey="Weintraub D">D Weintraub</name></author><author><name sortKey="Koester, J" uniqKey="Koester J">J Koester</name></author><author><name sortKey="Potenza, Mn" uniqKey="Potenza M">MN Potenza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Evans, Ah" uniqKey="Evans A">AH Evans</name></author><author><name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Voon, V" uniqKey="Voon V">V Voon</name></author><author><name sortKey="Fox, Sh" uniqKey="Fox S">SH Fox</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pontone, G" uniqKey="Pontone G">G Pontone</name></author><author><name sortKey="Williams, Jr" uniqKey="Williams J">JR Williams</name></author><author><name sortKey="Bassett, Ss" uniqKey="Bassett S">SS Bassett</name></author><author><name sortKey="Marsh, L" uniqKey="Marsh L">L Marsh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nirenberg, Mj" uniqKey="Nirenberg M">MJ Nirenberg</name></author><author><name sortKey="Waters, C" uniqKey="Waters C">C Waters</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Miyasaki, Jm" uniqKey="Miyasaki J">JM Miyasaki</name></author><author><name sortKey="Al Hassan, K" uniqKey="Al Hassan K">K Al Hassan</name></author><author><name sortKey="Lang, Ae" uniqKey="Lang A">AE Lang</name></author><author><name sortKey="Voon, V" uniqKey="Voon V">V Voon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lawrence, Aj" uniqKey="Lawrence A">AJ Lawrence</name></author><author><name sortKey="Blackwell, Ad" uniqKey="Blackwell A">AD Blackwell</name></author><author><name sortKey="Barker, Ra" uniqKey="Barker R">RA Barker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weintraub, D" uniqKey="Weintraub D">D Weintraub</name></author><author><name sortKey="Siderowf, Ad" uniqKey="Siderowf A">AD Siderowf</name></author><author><name sortKey="Potenza, Mn" uniqKey="Potenza M">MN Potenza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Voon, V" uniqKey="Voon V">V Voon</name></author><author><name sortKey="Mehta, Ar" uniqKey="Mehta A">AR Mehta</name></author><author><name sortKey="Hallett, M" uniqKey="Hallett M">M Hallett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Voon, V" uniqKey="Voon V">V Voon</name></author><author><name sortKey="Sohr, M" uniqKey="Sohr M">M Sohr</name></author><author><name sortKey="Lang, Ae" uniqKey="Lang A">AE Lang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weintraub, D" uniqKey="Weintraub D">D Weintraub</name></author><author><name sortKey="Stewart, S" uniqKey="Stewart S">S Stewart</name></author><author><name sortKey="Shea, Ja" uniqKey="Shea J">JA Shea</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ardouin, C" uniqKey="Ardouin C">C Ardouin</name></author><author><name sortKey="Chereau, I" uniqKey="Chereau I">I Chéreau</name></author><author><name sortKey="Llorca, Pm" uniqKey="Llorca P">PM Llorca</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cilia, R" uniqKey="Cilia R">R Cilia</name></author><author><name sortKey="Siri, C" uniqKey="Siri C">C Siri</name></author><author><name sortKey="Marotta, G" uniqKey="Marotta G">G Marotta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Eimeren, T" uniqKey="Van Eimeren T">T Van Eimeren</name></author><author><name sortKey="Pellecchia, G" uniqKey="Pellecchia G">G Pellecchia</name></author><author><name sortKey="Cilia, R" uniqKey="Cilia R">R Cilia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Voon, V" uniqKey="Voon V">V Voon</name></author><author><name sortKey="Pessiglione, M" uniqKey="Pessiglione M">M Pessiglione</name></author><author><name sortKey="Brezing, C" uniqKey="Brezing C">C Brezing</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carter, A" uniqKey="Carter A">A Carter</name></author><author><name sortKey="Ambermoon, P" uniqKey="Ambermoon P">P Ambermoon</name></author><author><name sortKey="Hall, Wd" uniqKey="Hall W">WD Hall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mamikonyan, E" uniqKey="Mamikonyan E">E Mamikonyan</name></author><author><name sortKey="Siderowf, Ad" uniqKey="Siderowf A">AD Siderowf</name></author><author><name sortKey="Duda, Je" uniqKey="Duda J">JE Duda</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dubois, B" uniqKey="Dubois B">B Dubois</name></author><author><name sortKey="Pillon, B" uniqKey="Pillon B">B Pillon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aarsland, D" uniqKey="Aarsland D">D Aarsland</name></author><author><name sortKey="Zaccai, J" uniqKey="Zaccai J">J Zaccai</name></author><author><name sortKey="Brayne, C" uniqKey="Brayne C">C Brayne</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Lau, Lml" uniqKey="De Lau L">LML De Lau</name></author><author><name sortKey="Schipper, Cma" uniqKey="Schipper C">CMA Schipper</name></author><author><name sortKey="Hofman, A" uniqKey="Hofman A">A Hofman</name></author><author><name sortKey="Koudstaal, Pj" uniqKey="Koudstaal P">PJ Koudstaal</name></author><author><name sortKey="Breteler, Mmb" uniqKey="Breteler M">MMB Breteler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hughes, Ta" uniqKey="Hughes T">TA Hughes</name></author><author><name sortKey="Ross, Hf" uniqKey="Ross H">HF Ross</name></author><author><name sortKey="Musa, S" uniqKey="Musa S">S Musa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aarsland, D" uniqKey="Aarsland D">D Aarsland</name></author><author><name sortKey="Andersen, K" uniqKey="Andersen K">K Andersen</name></author><author><name sortKey="Larsen, Jp" uniqKey="Larsen J">JP Larsen</name></author><author><name sortKey="Lolk, A" uniqKey="Lolk A">A Lolk</name></author><author><name sortKey="Nielsen, H" uniqKey="Nielsen H">H Nielsen</name></author><author><name sortKey="Kragh S Rensen, P" uniqKey="Kragh S Rensen P">P Kragh-Sørensen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bohnen, Ni" uniqKey="Bohnen N">NI Bohnen</name></author><author><name sortKey="Kaufer, Di" uniqKey="Kaufer D">DI Kaufer</name></author><author><name sortKey="Ivanco, Ls" uniqKey="Ivanco L">LS Ivanco</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aarsland, D" uniqKey="Aarsland D">D Aarsland</name></author><author><name sortKey="Mosimann, Up" uniqKey="Mosimann U">UP Mosimann</name></author><author><name sortKey="Mckeith, Ig" uniqKey="Mckeith I">IG McKeith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cummings, Jl" uniqKey="Cummings J">JL Cummings</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Forsaa, Eb" uniqKey="Forsaa E">EB Forsaa</name></author><author><name sortKey="Larsen, Jp" uniqKey="Larsen J">JP Larsen</name></author><author><name sortKey="Wentzel Larsen, T" uniqKey="Wentzel Larsen T">T Wentzel-Larsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fenelon, G" uniqKey="Fenelon G">G Fénelon</name></author><author><name sortKey="Mahieux, F" uniqKey="Mahieux F">F Mahieux</name></author><author><name sortKey="Huon, R" uniqKey="Huon R">R Huon</name></author><author><name sortKey="Ziegler, M" uniqKey="Ziegler M">M Ziégler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fenelon, G" uniqKey="Fenelon G">G Fenelon</name></author><author><name sortKey="Alves, G" uniqKey="Alves G">G Alves</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Diederich, Nj" uniqKey="Diederich N">NJ Diederich</name></author><author><name sortKey="Goetz, Cg" uniqKey="Goetz C">CG Goetz</name></author><author><name sortKey="Raman, R" uniqKey="Raman R">R Raman</name></author><author><name sortKey="Pappert, Ej" uniqKey="Pappert E">EJ Pappert</name></author><author><name sortKey="Leurgans, S" uniqKey="Leurgans S">S Leurgans</name></author><author><name sortKey="Piery, V" uniqKey="Piery V">V Piery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arnulf, I" uniqKey="Arnulf I">I Arnulf</name></author><author><name sortKey="Bonnet, Am" uniqKey="Bonnet A">AM Bonnet</name></author><author><name sortKey="Damier, P" uniqKey="Damier P">P Damier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Factor, Sa" uniqKey="Factor S">SA Factor</name></author><author><name sortKey="Feustel, Pj" uniqKey="Feustel P">PJ Feustel</name></author><author><name sortKey="Friedman, Jh" uniqKey="Friedman J">JH Friedman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levy, G" uniqKey="Levy G">G Levy</name></author><author><name sortKey="Tang, Mx" uniqKey="Tang M">MX Tang</name></author><author><name sortKey="Louis, Ed" uniqKey="Louis E">ED Louis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fenelon, G" uniqKey="Fenelon G">G Fénelon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ibarretxe Bilbao, N" uniqKey="Ibarretxe Bilbao N">N Ibarretxe-Bilbao</name></author><author><name sortKey="Junque, C" uniqKey="Junque C">C Junque</name></author><author><name sortKey="Marti, Mj" uniqKey="Marti M">MJ Marti</name></author><author><name sortKey="Tolosa, E" uniqKey="Tolosa E">E Tolosa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ramirez Ruiz, B" uniqKey="Ramirez Ruiz B">B Ramírez-Ruiz</name></author><author><name sortKey="Marti, Mj" uniqKey="Marti M">MJ Martí</name></author><author><name sortKey="Tolosa, E" uniqKey="Tolosa E">E Tolosa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Williams, Dr" uniqKey="Williams D">DR Williams</name></author><author><name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Friedman, Jh" uniqKey="Friedman J">JH Friedman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koller, Wc" uniqKey="Koller W">WC Koller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Ma" uniqKey="Lee M">MA Lee</name></author><author><name sortKey="Walker, Rw" uniqKey="Walker R">RW Walker</name></author><author><name sortKey="Hildreth, Tj" uniqKey="Hildreth T">TJ Hildreth</name></author><author><name sortKey="Prentice, Wm" uniqKey="Prentice W">WM Prentice</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Defazio, G" uniqKey="Defazio G">G Defazio</name></author><author><name sortKey="Berardelli, A" uniqKey="Berardelli A">A Berardelli</name></author><author><name sortKey="Fabbrini, G" uniqKey="Fabbrini G">G Fabbrini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Negre Pages, L" uniqKey="Negre Pages L">L Nègre-Pagès</name></author><author><name sortKey="Regragui, W" uniqKey="Regragui W">W Regragui</name></author><author><name sortKey="Bouhassira, D" uniqKey="Bouhassira D">D Bouhassira</name></author><author><name sortKey="Grandjean, H" uniqKey="Grandjean H">H Grandjean</name></author><author><name sortKey="Rascol, O" uniqKey="Rascol O">O Rascol</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goetz, Cg" uniqKey="Goetz C">CG Goetz</name></author><author><name sortKey="Tanner, Cm" uniqKey="Tanner C">CM Tanner</name></author><author><name sortKey="Levy, M" uniqKey="Levy M">M Levy</name></author><author><name sortKey="Wilson, Rs" uniqKey="Wilson R">RS Wilson</name></author><author><name sortKey="Garron, Dc" uniqKey="Garron D">DC Garron</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ford, B" uniqKey="Ford B">B Ford</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ha, Ad" uniqKey="Ha A">AD Ha</name></author><author><name sortKey="Jankovic, J" uniqKey="Jankovic J">J Jankovic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beiske, Ag" uniqKey="Beiske A">AG Beiske</name></author><author><name sortKey="Loge, Jh" uniqKey="Loge J">JH Loge</name></author><author><name sortKey="R Nningen, A" uniqKey="R Nningen A">A Rønningen</name></author><author><name sortKey="Svensson, E" uniqKey="Svensson E">E Svensson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Djaldetti, R" uniqKey="Djaldetti R">R Djaldetti</name></author><author><name sortKey="Shifrin, A" uniqKey="Shifrin A">A Shifrin</name></author><author><name sortKey="Rogowski, Z" uniqKey="Rogowski Z">Z Rogowski</name></author><author><name sortKey="Sprecher, E" uniqKey="Sprecher E">E Sprecher</name></author><author><name sortKey="Melamed, E" uniqKey="Melamed E">E Melamed</name></author><author><name sortKey="Yarnitsky, D" uniqKey="Yarnitsky D">D Yarnitsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brefel Courbon, C" uniqKey="Brefel Courbon C">C Brefel-Courbon</name></author><author><name sortKey="Payoux, P" uniqKey="Payoux P">P Payoux</name></author><author><name sortKey="Thalamas, C" uniqKey="Thalamas C">C Thalamas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lavreysen, H" uniqKey="Lavreysen H">H Lavreysen</name></author><author><name sortKey="Dautzenberg, Fm" uniqKey="Dautzenberg F">FM Dautzenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Djaldetti, R" uniqKey="Djaldetti R">R Djaldetti</name></author><author><name sortKey="Yust Katz, S" uniqKey="Yust Katz S">S Yust-Katz</name></author><author><name sortKey="Kolianov, V" uniqKey="Kolianov V">V Kolianov</name></author><author><name sortKey="Melamed, E" uniqKey="Melamed E">E Melamed</name></author><author><name sortKey="Dabby, R" uniqKey="Dabby R">R Dabby</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barone, P" uniqKey="Barone P">P Barone</name></author><author><name sortKey="Antonini, A" uniqKey="Antonini A">A Antonini</name></author><author><name sortKey="Colossimo, C" uniqKey="Colossimo C">C Colossimo</name></author><author><name sortKey="Marconi, R" uniqKey="Marconi R">R Marconi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arnulf, I" uniqKey="Arnulf I">I Arnulf</name></author><author><name sortKey="Konofal, E" uniqKey="Konofal E">E Konofal</name></author><author><name sortKey="Merino Andreu, M" uniqKey="Merino Andreu M">M Merino-Andreu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garcia Borreguero, D" uniqKey="Garcia Borreguero D">D Garcia-Borreguero</name></author><author><name sortKey="Odin, P" uniqKey="Odin P">P Odin</name></author><author><name sortKey="Serrano, C" uniqKey="Serrano C">C Serrano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arnulf, I" uniqKey="Arnulf I">I Arnulf</name></author><author><name sortKey="Leu, S" uniqKey="Leu S">S Leu</name></author><author><name sortKey="Oudiette, D" uniqKey="Oudiette D">D Oudiette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iranzo, A" uniqKey="Iranzo A">A Iranzo</name></author><author><name sortKey="Lome A, F" uniqKey="Lome A F">F Lomeña</name></author><author><name sortKey="Stockner, H" uniqKey="Stockner H">H Stockner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pal, Pk" uniqKey="Pal P">PK Pal</name></author><author><name sortKey="Calne, S" uniqKey="Calne S">S Calne</name></author><author><name sortKey="Samii, A" uniqKey="Samii A">A Samii</name></author><author><name sortKey="Fleming, Jae" uniqKey="Fleming J">JAE Fleming</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tandberg, E" uniqKey="Tandberg E">E Tandberg</name></author><author><name sortKey="Larsen, Jp" uniqKey="Larsen J">JP Larsen</name></author><author><name sortKey="Karlsen, K" uniqKey="Karlsen K">K Karlsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Diederich, Nj" uniqKey="Diederich N">NJ Diederich</name></author><author><name sortKey="Mcintyre, Dj" uniqKey="Mcintyre D">DJ McIntyre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barone, P" uniqKey="Barone P">P Barone</name></author><author><name sortKey="Amboni, M" uniqKey="Amboni M">M Amboni</name></author><author><name sortKey="Vitale, C" uniqKey="Vitale C">C Vitale</name></author><author><name sortKey="Bonavita, V" uniqKey="Bonavita V">V Bonavita</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Post, Kk" uniqKey="Post K">KK Post</name></author><author><name sortKey="Singer, C" uniqKey="Singer C">C Singer</name></author><author><name sortKey="Papapetropoulos, S" uniqKey="Papapetropoulos S">S Papapetropoulos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Visser, M" uniqKey="Visser M">M Visser</name></author><author><name sortKey="Marinus, J" uniqKey="Marinus J">J Marinus</name></author><author><name sortKey="Stiggelbout, Am" uniqKey="Stiggelbout A">AM Stiggelbout</name></author><author><name sortKey="Van Hilten, Jj" uniqKey="Van Hilten J">JJ van Hilten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sakakibara, R" uniqKey="Sakakibara R">R Sakakibara</name></author><author><name sortKey="Uchiyama, T" uniqKey="Uchiyama T">T Uchiyama</name></author><author><name sortKey="Yamanishi, T" uniqKey="Yamanishi T">T Yamanishi</name></author><author><name sortKey="Kishi, M" uniqKey="Kishi M">M Kishi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sakakibara, R" uniqKey="Sakakibara R">R Sakakibara</name></author><author><name sortKey="Shinotoh, H" uniqKey="Shinotoh H">H Shinotoh</name></author><author><name sortKey="Uchiyama, T" uniqKey="Uchiyama T">T Uchiyama</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gao, X" uniqKey="Gao X">X Gao</name></author><author><name sortKey="Chen, H" uniqKey="Chen H">H Chen</name></author><author><name sortKey="Schwarzschild, Ma" uniqKey="Schwarzschild M">MA Schwarzschild</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lahrmann, H" uniqKey="Lahrmann H">H Lahrmann</name></author><author><name sortKey="Cortelli, P" uniqKey="Cortelli P">P Cortelli</name></author><author><name sortKey="Hilz, M" uniqKey="Hilz M">M Hilz</name></author><author><name sortKey="Mathias, Cj" uniqKey="Mathias C">CJ Mathias</name></author><author><name sortKey="Struhal, W" uniqKey="Struhal W">W Struhal</name></author><author><name sortKey="Tassinari, M" uniqKey="Tassinari M">M Tassinari</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Senard, Jm" uniqKey="Senard J">JM Senard</name></author><author><name sortKey="Pathak, A" uniqKey="Pathak A">A Pathak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Senard, Jm" uniqKey="Senard J">JM Senard</name></author><author><name sortKey="Rai, S" uniqKey="Rai S">S Raï</name></author><author><name sortKey="Lapeyre Mestre, M" uniqKey="Lapeyre Mestre M">M Lapeyre-Mestre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Senard, Jm" uniqKey="Senard J">JM Senard</name></author><author><name sortKey="Valet, P" uniqKey="Valet P">P Valet</name></author><author><name sortKey="Durrieu, G" uniqKey="Durrieu G">G Durrieu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Senard, Jm" uniqKey="Senard J">JM Senard</name></author><author><name sortKey="Brefel Courbon, C" uniqKey="Brefel Courbon C">C Brefel-Courbon</name></author><author><name sortKey="Rascol, O" uniqKey="Rascol O">O Rascol</name></author><author><name sortKey="Montastruc, Jl" uniqKey="Montastruc J">JL Montastruc</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Allcock, Lm" uniqKey="Allcock L">LM Allcock</name></author><author><name sortKey="Kenny, Ra" uniqKey="Kenny R">RA Kenny</name></author><author><name sortKey="Burn, Dj" uniqKey="Burn D">DJ Burn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Savica, R" uniqKey="Savica R">R Savica</name></author><author><name sortKey="Carlin, Jm" uniqKey="Carlin J">JM Carlin</name></author><author><name sortKey="Grossardt, Br" uniqKey="Grossardt B">BR Grossardt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abbott, Rd" uniqKey="Abbott R">RD Abbott</name></author><author><name sortKey="Petrovitch, H" uniqKey="Petrovitch H">H Petrovitch</name></author><author><name sortKey="White, Lr" uniqKey="White L">LR White</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sakakibara, R" uniqKey="Sakakibara R">R Sakakibara</name></author><author><name sortKey="Uchiyama, T" uniqKey="Uchiyama T">T Uchiyama</name></author><author><name sortKey="Yamanishi, T" uniqKey="Yamanishi T">T Yamanishi</name></author><author><name sortKey="Shirai, K" uniqKey="Shirai K">K Shirai</name></author><author><name sortKey="Hattori, T" uniqKey="Hattori T">T Hattori</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stacy, M" uniqKey="Stacy M">M Stacy</name></author><author><name sortKey="Hauser, R" uniqKey="Hauser R">R Hauser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bayulkem, K" uniqKey="Bayulkem K">K Bayulkem</name></author><author><name sortKey="Lopez, G" uniqKey="Lopez G">G Lopez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fox, Sh" uniqKey="Fox S">SH Fox</name></author><author><name sortKey="Lang, Ae" uniqKey="Lang A">AE Lang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Riley, De" uniqKey="Riley D">DE Riley</name></author><author><name sortKey="Lang, Ae" uniqKey="Lang A">AE Lang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaudhuri, Kr" uniqKey="Chaudhuri K">KR Chaudhuri</name></author><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author><author><name sortKey="Schapira, Ahv" uniqKey="Schapira A">AHV Schapira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author><author><name sortKey="Rodriguez Blazquez, C" uniqKey="Rodriguez Blazquez C">C Rodriguez-Blazquez</name></author><author><name sortKey="Abe, K" uniqKey="Abe K">K Abe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gallagher, Da" uniqKey="Gallagher D">DA Gallagher</name></author><author><name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name></author><author><name sortKey="Schrag, A" uniqKey="Schrag A">A Schrag</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaudhuri, Kr" uniqKey="Chaudhuri K">KR Chaudhuri</name></author><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author><author><name sortKey="Brown, Rg" uniqKey="Brown R">RG Brown</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marinus, J" uniqKey="Marinus J">J Marinus</name></author><author><name sortKey="Visser, M" uniqKey="Visser M">M Visser</name></author><author><name sortKey="Stiggelbout, Am" uniqKey="Stiggelbout A">AM Stiggelbout</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Visser, M" uniqKey="Visser M">M Visser</name></author><author><name sortKey="Marinus, J" uniqKey="Marinus J">J Marinus</name></author><author><name sortKey="Stiggelbout, Am" uniqKey="Stiggelbout A">AM Stiggelbout</name></author><author><name sortKey="Van Hilten, Jj" uniqKey="Van Hilten J">JJ van Hilten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Verbaan, D" uniqKey="Verbaan D">D Verbaan</name></author><author><name sortKey="Marinus, J" uniqKey="Marinus J">J Marinus</name></author><author><name sortKey="Visser, M" uniqKey="Visser M">M Visser</name></author><author><name sortKey="Van Rooden, Sm" uniqKey="Van Rooden S">SM Van Rooden</name></author><author><name sortKey="Stiggelbout, Am" uniqKey="Stiggelbout A">AM Stiggelbout</name></author><author><name sortKey="Van Hilten, Jj" uniqKey="Van Hilten J">JJ Van Hilten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rendas Baum, R" uniqKey="Rendas Baum R">R Rendas-Baum</name></author><author><name sortKey="Buck, Po" uniqKey="Buck P">PO Buck</name></author><author><name sortKey="White, Mk" uniqKey="White M">MK White</name></author><author><name sortKey="Castelli Haley, J" uniqKey="Castelli Haley J">J Castelli-Haley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goetz, Cg" uniqKey="Goetz C">CG Goetz</name></author><author><name sortKey="Tilley, Bc" uniqKey="Tilley B">BC Tilley</name></author><author><name sortKey="Shaftman, Sr" uniqKey="Shaftman S">SR Shaftman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gallagher, Da" uniqKey="Gallagher D">DA Gallagher</name></author><author><name sortKey="Goetz, Cg" uniqKey="Goetz C">CG Goetz</name></author><author><name sortKey="Stebbins, G" uniqKey="Stebbins G">G Stebbins</name></author><author><name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name></author><author><name sortKey="Schrag, A" uniqKey="Schrag A">A Schrag</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kleiner Fisman, G" uniqKey="Kleiner Fisman G">G Kleiner-Fisman</name></author><author><name sortKey="Martine, R" uniqKey="Martine R">R Martine</name></author><author><name sortKey="Lang, Ae" uniqKey="Lang A">AE Lang</name></author><author><name sortKey="Stern, Mb" uniqKey="Stern M">MB Stern</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hogl, B" uniqKey="Hogl B">B Högl</name></author><author><name sortKey="Arnulf, I" uniqKey="Arnulf I">I Arnulf</name></author><author><name sortKey="Comella, C" uniqKey="Comella C">C Comella</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weintraub, D" uniqKey="Weintraub D">D Weintraub</name></author><author><name sortKey="Hoops, S" uniqKey="Hoops S">S Hoops</name></author><author><name sortKey="Shea, Ja" uniqKey="Shea J">JA Shea</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lang, Ae" uniqKey="Lang A">AE Lang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tolosa, E" uniqKey="Tolosa E">E Tolosa</name></author><author><name sortKey="Gaig, C" uniqKey="Gaig C">C Gaig</name></author><author><name sortKey="Santamaria, J" uniqKey="Santamaria J">J Santamaría</name></author><author><name sortKey="Compta, Y" uniqKey="Compta Y">Y Compta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ponsen, Mm" uniqKey="Ponsen M">MM Ponsen</name></author><author><name sortKey="Stoffers, D" uniqKey="Stoffers D">D Stoffers</name></author><author><name sortKey="Booij, J" uniqKey="Booij J">J Booij</name></author><author><name sortKey="Van Eck Smit, Blf" uniqKey="Van Eck Smit B">BLF Van Eck-Smit</name></author><author><name sortKey="Wolters, Ec" uniqKey="Wolters E">EC Wolters</name></author><author><name sortKey="Berendse, Hw" uniqKey="Berendse H">HW Berendse</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ross, Gw" uniqKey="Ross G">GW Ross</name></author><author><name sortKey="Petrovitch, H" uniqKey="Petrovitch H">H Petrovitch</name></author><author><name sortKey="Abbott, Rd" uniqKey="Abbott R">RD Abbott</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abbott, Rd" uniqKey="Abbott R">RD Abbott</name></author><author><name sortKey="Ross, Gw" uniqKey="Ross G">GW Ross</name></author><author><name sortKey="Petrovitch, H" uniqKey="Petrovitch H">H Petrovitch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Braak, H" uniqKey="Braak H">H Braak</name></author><author><name sortKey="Bohl, Jr" uniqKey="Bohl J">JR Bohl</name></author><author><name sortKey="Muller, Cm" uniqKey="Muller C">CM Müller</name></author><author><name sortKey="Rub, U" uniqKey="Rub U">U Rüb</name></author><author><name sortKey="De Vos, Rai" uniqKey="De Vos R">RAI de Vos</name></author><author><name sortKey="Del Tredici, K" uniqKey="Del Tredici K">K Del Tredici</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lebouvier, T" uniqKey="Lebouvier T">T Lebouvier</name></author><author><name sortKey="Chaumette, T" uniqKey="Chaumette T">T Chaumette</name></author><author><name sortKey="Damier, P" uniqKey="Damier P">P Damier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leentjens, Afg" uniqKey="Leentjens A">AFG Leentjens</name></author><author><name sortKey="Van Den Akker, M" uniqKey="Van Den Akker M">M Van den Akker</name></author><author><name sortKey="Metsemakers, Jfm" uniqKey="Metsemakers J">JFM Metsemakers</name></author><author><name sortKey="Lousberg, R" uniqKey="Lousberg R">R Lousberg</name></author><author><name sortKey="Verhey, Frj" uniqKey="Verhey F">FRJ Verhey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tandberg, E" uniqKey="Tandberg E">E Tandberg</name></author><author><name sortKey="Larsen, Jp" uniqKey="Larsen J">JP Larsen</name></author><author><name sortKey="Karlsen, K" uniqKey="Karlsen K">K Karlsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kumar, S" uniqKey="Kumar S">S Kumar</name></author><author><name sortKey="Bhatia, M" uniqKey="Bhatia M">M Bhatia</name></author><author><name sortKey="Behari, M" uniqKey="Behari M">M Behari</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iranzo, A" uniqKey="Iranzo A">A Iranzo</name></author><author><name sortKey="Molinuevo, Jl" uniqKey="Molinuevo J">JL Molinuevo</name></author><author><name sortKey="Santamaria, J" uniqKey="Santamaria J">J Santamaría</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iranzo, A" uniqKey="Iranzo A">A Iranzo</name></author><author><name sortKey="Lome A, F" uniqKey="Lome A F">F Lomeña</name></author><author><name sortKey="Stockner, H" uniqKey="Stockner H">H Stockner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Postuma, Rb" uniqKey="Postuma R">RB Postuma</name></author><author><name sortKey="Montplaisir, J" uniqKey="Montplaisir J">J Montplaisir</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Braak, H" uniqKey="Braak H">H Braak</name></author><author><name sortKey="Del Tredici, K" uniqKey="Del Tredici K">K Del Tredici</name></author><author><name sortKey="Rub, U" uniqKey="Rub U">U Rüb</name></author><author><name sortKey="De Vos, Rai" uniqKey="De Vos R">RAI De Vos</name></author><author><name sortKey="Jansen Steur, Enh" uniqKey="Jansen Steur E">ENH Jansen Steur</name></author><author><name sortKey="Braak, E" uniqKey="Braak E">E Braak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Forno, Ls" uniqKey="Forno L">LS Forno</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaudhuri, Kr" uniqKey="Chaudhuri K">KR Chaudhuri</name></author><author><name sortKey="Prieto Jurcynska, C" uniqKey="Prieto Jurcynska C">C Prieto-Jurcynska</name></author><author><name sortKey="Naidu, Y" uniqKey="Naidu Y">Y Naidu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shulman, Lm" uniqKey="Shulman L">LM Shulman</name></author><author><name sortKey="Taback, Rl" uniqKey="Taback R">RL Taback</name></author><author><name sortKey="Rabinstein, Aa" uniqKey="Rabinstein A">AA Rabinstein</name></author><author><name sortKey="Weiner, Wj" uniqKey="Weiner W">WJ Weiner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name></author><author><name sortKey="Rodriguez Blazquez, C" uniqKey="Rodriguez Blazquez C">C Rodriguez-Blazquez</name></author><author><name sortKey="Kurtis, Mm" uniqKey="Kurtis M">MM Kurtis</name></author><author><name sortKey="Chaudhuri, Kr" uniqKey="Chaudhuri K">KR Chaudhuri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leonardi, M" uniqKey="Leonardi M">M Leonardi</name></author><author><name sortKey="Raggi, A" uniqKey="Raggi A">A Raggi</name></author><author><name sortKey="Pagani, M" uniqKey="Pagani M">M Pagani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hinnel, C" uniqKey="Hinnel C">C Hinnel</name></author><author><name sortKey="Hurt, Cs" uniqKey="Hurt C">CS Hurt</name></author><author><name sortKey="Landau, S" uniqKey="Landau S">S Landau</name></author><author><name sortKey="Brown, Rg" uniqKey="Brown R">RG Brown</name></author><author><name sortKey="Samuel, M" uniqKey="Samuel M">M Samuel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Visser, M" uniqKey="Visser M">M Visser</name></author><author><name sortKey="Van Rooden, Sm" uniqKey="Van Rooden S">SM Van Rooden</name></author><author><name sortKey="Verbaan, D" uniqKey="Verbaan D">D Verbaan</name></author><author><name sortKey="Marinus, J" uniqKey="Marinus J">J Marinus</name></author><author><name sortKey="Stiggelbout, Am" uniqKey="Stiggelbout A">AM Stiggelbout</name></author><author><name sortKey="Van Hilten, Jj" uniqKey="Van Hilten J">JJ Van Hilten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zesiewicz, Ta" uniqKey="Zesiewicz T">TA Zesiewicz</name></author><author><name sortKey="Sullivan, Kl" uniqKey="Sullivan K">KL Sullivan</name></author><author><name sortKey="Arnulf, I" uniqKey="Arnulf I">I Arnulf</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">Parkinsons Dis</journal-id><journal-id journal-id-type="publisher-id">PD</journal-id><journal-title-group><journal-title>Parkinson's Disease</journal-title></journal-title-group><issn pub-type="ppub">2090-8083</issn><issn pub-type="epub">2042-0080</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22888466</article-id><article-id pub-id-type="pmc">3410355</article-id><article-id pub-id-type="doi">10.1155/2012/198316</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bonnet</surname><given-names>Anne Marie</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="aff" rid="I2"><sup>2</sup></xref><xref ref-type="aff" rid="I3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Jutras</surname><given-names>Marie France</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Czernecki</surname><given-names>Virginie</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Corvol</surname><given-names>Jean Christophe</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="aff" rid="I2"><sup>2</sup></xref><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vidailhet</surname><given-names>Marie</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="aff" rid="I2"><sup>2</sup></xref><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>APHP, Department of Neurology, Hospital Pitié-Salpêtrière, Paris, France</aff><aff id="I2"><sup>2</sup>INSERM, APHP, ICM, Centre d'Investigation Clinique, CIC-9503, Hospital Pitié-Salpêtrière, Paris, France</aff><aff id="I3"><sup>3</sup>INSERM, CR-ICM, UMRS 975, Hospital Pitié-Salpêtrière, Paris, France</aff><author-notes><corresp id="cor1">*Anne Marie Bonnet: <email>anne-marie.bonnet@psl.aphp.fr</email></corresp><fn fn-type="other"><p>Academic Editor: Marjan Jahanshahi</p></fn></author-notes><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>25</day><month>7</month><year>2012</year></pub-date><volume>2012</volume><elocation-id>198316</elocation-id><history><date date-type="received"><day>3</day><month>2</month><year>2012</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2012</year></date></history><permissions><copyright-statement>Copyright © 2012 Anne Marie Bonnet et al.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Nonmotor symptoms (NMSs) of Parkinson's disease (PD) are common, but they are often underrecognized in clinical practice, because of the lack of spontaneous complaints by the patients, and partly because of the absence of systematic questioning by the consulting physician. However, valid specific instruments for identification and assessment of these symptoms are available in 2012. The administration of the self-completed screening tool, NMSQuest, associated with questioning during the consultation, improves the diagnosis of NMSs. NMSs play a large role in degradation of quality of life. More relevant NMSs are described in this review, mood disorders, impulse control disorders, cognitive deficits, hallucinations, pain, sleep disorders, and dysautonomia.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Nonmotor symptoms (NMS) of Parkinson's disease (PD) are common, but yet are often underrecognized in clinical practice because of the lack of spontaneous complaints by the patients, and also the absence of systematic questioning by health care professionals.</p><p>NMSs in PD have been systematically described for the first time in 2006 by Chaudhuri et al. [<xref ref-type="bibr" rid="B1">1</xref>]. NMS are found in a large proportion of patients with PD [<xref ref-type="bibr" rid="B2">2</xref>], and these symptoms consist of autonomic dysfunction, sensory complaints, neuropsychiatric disturbances, sleep disorders, fatigue, and many others (<xref ref-type="table" rid="tab1">Table 1</xref>) [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>NMS occur throughout the course of the disease. Some of them, such as depression, fatigue, and olfactory disorders, may appear at the earliest stage of the disease, in not treated patients [<xref ref-type="bibr" rid="B4">4</xref>]. Sometimes, NMS can even precede the motor symptoms or signs by several years and then herald the onset of PD. These premotor symptoms include olfactory dysfunction, REM sleep behaviour disorder (RBD), constipation, depression, and pain [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. On the other hand, at advanced stage of the disease, NMS coexist for most patients with motor fluctuations [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>The frequency of NMS increases along with the disease duration [<xref ref-type="bibr" rid="B7">7</xref>]. At the time of diagnosis, the prevalence of NMS among PD patients is 21% (pain, urinary symptoms, depression, and anxiety) [<xref ref-type="bibr" rid="B8">8</xref>] and goes up to 88% after 7 years of disease progression [<xref ref-type="bibr" rid="B9">9</xref>]. In a recent international study, NMS such as constipation, bladder dysfunction, and feeling of sadness are reported by more than one-half of the patients, significantly more prevalent among PD patients than controls, and correlated with the duration of the disease [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B10">10</xref>].</p><p>Most of the nonmotor features associated with PD are presumably related to the involvement of the nondopaminergic systems, with the hypothesis of involvement of other neurotransmitters including serotoninergic, noradrenergic, and cholinergic transmission [<xref ref-type="bibr" rid="B11">11</xref>]. This is the case of depression in PD, which could depend on loss of dopaminergic and noradrenergic transmission in the limbic system [<xref ref-type="bibr" rid="B12">12</xref>]. Indeed, nondopaminergic therapies have an important role in the treatment of most NMS.</p><p>Nevertheless, dopaminergic dysfunction involvement may contribute to many NMS [<xref ref-type="bibr" rid="B13">13</xref>]. Depression, anxiety, and apathy seem to be partly related to hypodopaminergic transmission [<xref ref-type="bibr" rid="B14">14</xref>] and are improved by levodopa therapy. On the other hand, hyperdopaminergic transmission related to dopaminergic therapy can induce NMS, like dopamine dysregulation syndrome, drug-induced hallucinations and “psychosis,” hypomania, addiction to treatment, and impulse control disorders (ICD) [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>Nonmotor fluctuations (NMFs) are also dopamine-dependant NMS and may be improved by levodopa therapy, applying the continuous dopaminergic stimulation theory, in order to eliminate “off” periods [<xref ref-type="bibr" rid="B13">13</xref>]. </p><p>Many NMS, such as depression, can result in a major disability and seriously impact the quality of life [<xref ref-type="bibr" rid="B16">16</xref>]. In a study of several hundred patients, the score of NMS, evaluated with the non motor symptoms scale (NMSS) [<xref ref-type="bibr" rid="B17">17</xref>], is correlated with the score of PDQ-39 [<xref ref-type="bibr" rid="B18">18</xref>]. The more severe are the NMS, the more affected is the quality of life.</p><p>These facts highlight the importance that adequate tools to detect NMS, in order to optimize the treatment of PD patients. Accordingly, a more recent review has described the instruments available for the detection and assessment of NMS, as well as recommendations for their treatment [<xref ref-type="bibr" rid="B4">4</xref>]. Fortunately, specific and valid instruments may help clinicians to assess these symptoms although therapeutic strategies remain limited in 2012 [<xref ref-type="bibr" rid="B19">19</xref>]. This paper was recently published with the objective to update previous Evidence-Based Medicine reviews on treatments for NMS in PD. Only four treatments are considered efficacious: Pramipexole for the treatment of depressive symptoms, Clozapine for the treatment of psychosis, Rivastigmine for the treatment of dementia, and botulinum toxin for the treatment of sialorrhea [<xref ref-type="bibr" rid="B19">19</xref>]. </p></sec><sec id="sec2"><title>2. Description of Different NMS</title><sec id="sec2.1"><title>2.1. Mood Disturbances and Apathy</title><p>Like any other chronic incurable conditions, PD can be discouraging for the patient and his family, but the pathology of PD in itself might predispose to anxiety and depression, through dysfunction of specific pathways. Depression, anxiety, and fatigue are not recognized by neurologists in almost one-half of consultations. Mood or behavioral disorders should be assessed by systematic questioning during the consultation and with specific scales in research context. </p><sec id="sec2.1.1"><title>2.1.1. Depression</title><p>Depression occurs at any stage of the disease, even at the beginning or sometimes many years before the onset of the disease [<xref ref-type="bibr" rid="B20">20</xref>]. Depression can occur in up to 27.6% of PD patients during early stages of the disease [<xref ref-type="bibr" rid="B21">21</xref>]. There is no correlation between depression and motor disability or cognitive decline [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>Depression may consist in major depressive disorder (17%), minor depressive disorder (22%), and dysthymia (13%), and clinical significant depressive symptoms are present in 35% of PD patients [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>]. However, the presentation of depression in PD is different from the classical features. In PD patients, predominant features are somatic (lack of energy, psychomotor slowing), with irritability, but no guilty or failing feeling. Depression is associated with sleep disorders, lack of refreshing sleep, decrease of libido, and feeling of poor physical appearance [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>PD patient with depression encounters difficulties to express their emotions and considers first the motor disability. Our perception of the PD patient's disability caused by the depression has to take into account resigned complaints of patients, and their difficulties to enter into a relationship with others. Also, other PD associated symptoms may obscure the diagnosis of depression, particularly motor symptoms such as akinesia, but also apathy, and anxiety [<xref ref-type="bibr" rid="B23">23</xref>]. </p><p>Depression may involve specific neuronal pathways: raphe nuclei (serotoninergic), locus coeruleus (noradrenergic), amygdala, cingular cortex, and mesolimbic and mesocortical mesothalamic pathways (dopaminergic) [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Antidepressant medications employed in PD depression include tricyclic antidepressants, selective serotonin reuptake inhibitors [<xref ref-type="bibr" rid="B26">25</xref>, <xref ref-type="bibr" rid="B27">26</xref>], and therapies acting on several neurotransmitters (e.g., noradrenergic and serotoninergic medication). Depression associated with “off” periods is improved by optimization of levodopatherapy. Cognitive behavioral therapy is effective in PD depression [<xref ref-type="bibr" rid="B28">27</xref>].</p></sec><sec id="sec2.1.2"><title>2.1.2. Anxiety</title><p>Generalized anxiety (with a feeling of situational insecurity) appears to be frequent in PD, as well as single phobia, social phobia, and panic trouble. Anxiety is two times more frequent in PD compared with the general population. The presence of anxiety symptoms has been found in 20 to 46% of PD patients [<xref ref-type="bibr" rid="B29">28</xref>]. During the course of the disease, 30 to 50% of PD patients experience anxiety [<xref ref-type="bibr" rid="B30">29</xref>, <xref ref-type="bibr" rid="B31">30</xref>], which can be partly explained by the burden of the disease.</p><p>Risk factors for anxiety disorders are female gender, presence of motor fluctuations, and previous history of anxiety disorders [<xref ref-type="bibr" rid="B32">31</xref>]. It also occurs more frequently in young patients. Anxiety can be disabling, leading to social isolation and aggressiveness. When anxiety is present, depression is not so far [<xref ref-type="bibr" rid="B33">32</xref>]. Moreover, anxiety can worsen other parkinsonian symptoms, such as cognitive, but also motor symptoms.</p><p>Anxiety is often related to motor fluctuations, occurring just before intrusion of the “off” period, or being sustained during the “off” period [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Sometimes, anxiety can be quite challenging to diagnose, especially when manifesting as isolated aggressiveness, avoiding behaviors, expression difficulties, or cognitive disturbances.</p><p>Anxiety is often present long time before the onset of the disease, in the form of constant anxiety, panics attacks, or phobia [<xref ref-type="bibr" rid="B34">33</xref>].</p><p>Classically treated with benzodiazepines, anxiety is now treated with long lasting therapies, particularly serotoninergic medications also used for treatment of depression [<xref ref-type="bibr" rid="B35">34</xref>]. Compared to benzodiazepines, serotoninergic medication allows a long-term therapy, without inducing dependence. Anxiety linked to motor fluctuations is improved by adaptation of levodopatherapy, which reduces motor fluctuations. Adjunctive therapies such as psychotherapy are also performed. </p></sec><sec id="sec2.1.3"><title>2.1.3. Apathy</title><p>Recent literature has been focused on apathy. Apathy consists in a loss of motivation, which appears in emotional, intellectual domains and in the behavior. For the diagnosis of apathy, the decrease of spontaneous acting must not be imputable to motor disability, nor to severe cognitive decline [<xref ref-type="bibr" rid="B36">35</xref>, <xref ref-type="bibr" rid="B37">36</xref>]. Indeed, this neuropsychiatric symptom is frequent, with a prevalence of 30% to 40% in PD patients [<xref ref-type="bibr" rid="B38">37</xref>, <xref ref-type="bibr" rid="B39">38</xref>]. Apathy is one of the major determinants of a reduced quality of life in PD [<xref ref-type="bibr" rid="B40">39</xref>], even at early stages. As such, early diagnosis and efficient therapy are important in order to avoid further consequences on quality of life and disability.</p><p>In recent years, a new approach has been initiated in apathy. Apathy can be assessed by the decrease of voluntary behaviors [<xref ref-type="bibr" rid="B41">40</xref>], that is, behaviors effectively decided by the patient himself, and not induced by surrounding people. </p><p>Apathy and depressionare two distinct entities although it is not always easy to distinguish between those two symptoms. First, there is some overlap of symptoms: loss of interest, diminished pleasure in activities, or fatigue. Second, apathy could also be part of depression. On the other side, it has been suggested that apathy can occur in the absence of sadness, and depression can occur in the absence of apathy [<xref ref-type="bibr" rid="B42">41</xref>]. </p><p>The relationship between the incidence of apathy and the decrease of dopamine has been suggested [<xref ref-type="bibr" rid="B43">42</xref>]. Dopamine is known to be implicated in motivational process, attributing an attracting character to things and stimulating willingness to act. Motivation and decision to act were found recovered after an increase of dopaminergic therapy dosage in apathetic PD patients [<xref ref-type="bibr" rid="B44">43</xref>, <xref ref-type="bibr" rid="B45">44</xref>].</p><p>At the earliest stages of the disease, the occurrence of apathy is mostly dopamine dependant [<xref ref-type="bibr" rid="B46">45</xref>]. Whit more advanced stages of the disease the cognitive decline could contribute to the apathetic behaviour, through dysexecutive dysfunction (difficulties to plan an action, slowness of thinking). In this case, treatments acting on attentional capacities can be proposed. </p></sec></sec><sec id="sec2.2"><title>2.2. Dopamine Dysregulation Syndrome and Impulse Control Disorders</title><p>Also named hedonistic homeostatic dysregulation in PD, dopamine dysregulation syndrome (DDS) has been recently defined as compulsive use of dopaminergic drugs, associated with severe behavioral symptoms, and impaired social functioning [<xref ref-type="bibr" rid="B47">46</xref>, <xref ref-type="bibr" rid="B48">47</xref>]. DDS consists of a craving or intense desire to obtain medication, even in absence of motor parkinsonian symptoms. </p><p>Impulse control disorders (ICDs) are behavioral disorders characterized by failure to resist an impulse, inability to cut down and unsuccessful attempts to control a specific behavior. ICDs include pathological gambling, hypersexuality, compulsive shopping, and binge or compulsive eating. Another repetitive and compulsive behavior, the punding, has been described [<xref ref-type="bibr" rid="B49">48</xref>]. </p><p>Pathologic gambling is a failure to resist the urge to gamble, with persistent and recurrent maladaptive gambling behavior despite deleterious consequences on familial, occupational, and social functioning. Hypersexuality is characterized by a preoccupation with sexual thoughts, frequent demands and desires, and Internet pornography use or contact with sex workers [<xref ref-type="bibr" rid="B50">49</xref>]. Compulsive shopping is characterized by maladaptive preoccupation of buying or shopping, whether impulses or behaviors that are experienced as irresistible, intrusive, and/or senseless, resulting in frequent buying of more than can be afforded [<xref ref-type="bibr" rid="B51">50</xref>]. Compulsive eating refers to an uncontrollable consumption of a larger amount of food than normal in excess of that necessary to alleviate hunger [<xref ref-type="bibr" rid="B52">51</xref>]. Punding consists on an intense fascination, with repetitive handling, examining, sorting, and arranging of objects [<xref ref-type="bibr" rid="B53">52</xref>].</p><p>ICDs occur in 15% to 20% of PD patients, and their prevalence has been found increased among patients treated with a dopamine agonist, compared with patients not taking a dopamine agonist [<xref ref-type="bibr" rid="B48">47</xref>]. More precisely, pathological gambling has been found in 5% of PD patients, compulsive sexual behaviour in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3% [<xref ref-type="bibr" rid="B48">47</xref>]. Several ICDs can coexist in a given patient. Prevalence of DDS or punding behavior has not been studied as much as prevalence of ICD. About 4% of PD patients have been identified to have DDS [<xref ref-type="bibr" rid="B54">53</xref>]. Punding has been reported in 1.4% to 14% of PD patients according to different studies [<xref ref-type="bibr" rid="B49">48</xref>, <xref ref-type="bibr" rid="B53">52</xref>]. </p><p>In PD, ICDs appear in association with dopamine agonist therapy and are increased if combined with L-Dopa [<xref ref-type="bibr" rid="B55">54</xref>]. Nevertheless, individual vulnerability has been also evocated. The identified risk factors consist on a younger age, male gender, family history of addictive problems, depression, anxiety, and specific traits such as impulsivity and novelty seeking [<xref ref-type="bibr" rid="B56">55</xref>, <xref ref-type="bibr" rid="B57">56</xref>].</p><p>Screening instrument can assist in determining if a clinically significant problem exists. However, international validated screening tools for all ICDs occurring with PD treatment are still under investigation [<xref ref-type="bibr" rid="B58">57</xref>, <xref ref-type="bibr" rid="B59">58</xref>]. </p><p>Several hypotheses have been proposed to underlie those abnormal behaviors. Neural substrates research highlighted an overactivity in brain areas critically involved in reward and reward-based learning, motivation, impulse control, decision making and memory processing, namely, the basal ganglia, the orbitofrontal cortex, the hippocampus, the amygdala, and the insula. The dopaminergic therapy may stimulate mesolimbic circuitry related to engagement in motivated behaviors seen in ICDs. In PD, ventral striatal dopamine is relatively preserved compared to dorsal striatal activity. Dopaminergic treatment titrated to alleviate motor dorsal striatal deficiencies may result in an “over-dosing” in ventral corticostriatal cognitive and limbic pathways. Indeed, hyperdopaminergic levels induced by overstimulation of relatively preserved mesocorticolimbic dopamine pathway could result in ICD, compulsive use of medication, and punding behaviors, in patients with individual predisposition [<xref ref-type="bibr" rid="B47">46</xref>, <xref ref-type="bibr" rid="B56">55</xref>, <xref ref-type="bibr" rid="B60">59</xref>]. Dopamine agonist is also known to enhance learning from rewarding outcomes and reinforce impulse choice. Impulse control disorders could be the result of dysfunction of an inhibitor pathway concerning assessment of negative consequences of an action [<xref ref-type="bibr" rid="B61">60</xref>, <xref ref-type="bibr" rid="B62">61</xref>]. Thus, impulsive decisions associated with a distorted estimation of the consequences of actions (positive bias) could lead to abnormal behaviors with disastrous repercussions for everyday life.</p><p>Ethical issues and distress for subjects and their family (loss of employment and family break-up) have to be taken into consideration before initiating dopaminergic therapy in a young PD patient [<xref ref-type="bibr" rid="B63">62</xref>]. Many authors reported a dramatically improvement of the abnormal behavior after a dose reduction of the dopamine agonist therapy or a change to a different agonist [<xref ref-type="bibr" rid="B47">46</xref>, <xref ref-type="bibr" rid="B64">63</xref>]. </p></sec><sec id="sec2.3"><title>2.3. Cognitive Decline</title><p>It is important to distinguish mild cognitive impairment from dementia, the latter being present only in a moderate percentage of PD patients. In PD, very subtle cognitive disorders can develop insidiously within the first years of the disease. At this stage, cognitive deficits are not or few disabling in the context of daily life but, in a moderate proportion of cases, can progressively increase with the evolution of the disease. Cognitive disorders consist first of an intellectual slowing and difficulties to organize and manage the intellectual capacities, with preservation of global cognitive efficiency for long time [<xref ref-type="bibr" rid="B65">64</xref>]. Eventually, these disturbances can progressively increase with the time.</p><p>These cognitive disorders imply dysfunction of substantia nigra and nigrostriatal pathway. There is imbalance of striato-cortico-frontal pathways (which underlie the organisation of voluntary behaviors), causing a subcorticofrontal syndrome. Frontal subcortical syndrome in PD is implicated in all cognitive disorders, which are linked to dysfunction of the axis basal ganglia-frontal cortex. Frontal subcortical syndrome in PD is characterized by deficit of behavioral regulation in sorting or planning tasks, defective use of memory stores, and impaired manipulation of internal representation of visuospatial stimuli. There is a reduced speed of information treatment, psychomotor slowness, and also dysexecutive cognitive-behavioral syndrome.</p><p>Alteration of the ascending cholinergic and catecholaminergic neuronal systems may partly contribute to the frontal-lobe-like symptomatology associated with PD [<xref ref-type="bibr" rid="B65">64</xref>].</p><p>Dementia can be present at advanced stage of PD. Prevalence of dementia among PD patients is estimated between 20 and 30% according to the studies [<xref ref-type="bibr" rid="B66">65</xref>, <xref ref-type="bibr" rid="B67">66</xref>]. In a specific study, dementia is associated with older age at the onset of the disease, male sex, greater severity of neurological symptoms, longer duration of disease, and greater disability [<xref ref-type="bibr" rid="B68">67</xref>]. Older age at the entry into the disease and severity of motor symptoms are significant predictors of dementia [<xref ref-type="bibr" rid="B68">67</xref>].</p><p>Prevalence of PD dementia in the general population aged over 65 years old is from 0.2% to 0.5% [<xref ref-type="bibr" rid="B66">65</xref>]. Estimation of the incidence of dementia in PD requires prospective population-based studies: a study conducted on a large cohort of nondemented patients with PD concluded that the risk for developing dementia is six times higher in patients with PD compared with the general population [<xref ref-type="bibr" rid="B69">68</xref>].</p><p>Cortical activity of choline acetyltransferase, a marker of cortical cholinergic activity, is reduced in PD [<xref ref-type="bibr" rid="B70">69</xref>]. Cholinergic inhibitors have been shown to have a positive effect on cognition in PD dementia [<xref ref-type="bibr" rid="B71">70</xref>]. </p></sec><sec id="sec2.4"><title>2.4. Hallucinations, Delusions, and “Psychosis” </title><p>Psychotic symptoms (hallucinations, loss of insight, and delusions) affect most patients with PD. Psychosis is defined as hallucinations, delusions, or both, in patients with clear sensorium [<xref ref-type="bibr" rid="B72">71</xref>]. In PD, incidence of hallucinations is 80 for 1000 for year [<xref ref-type="bibr" rid="B73">72</xref>], more frequent in aging patients.</p><p>Hallucinations occur usually in a normal state of consciousness, without delirium, and have a chronic course [<xref ref-type="bibr" rid="B74">73</xref>]. The prevalence of complex visual hallucinations ranges from 22 to 38% [<xref ref-type="bibr" rid="B75">74</xref>]. Risk factors for hallucinations are older age, long duration of the disease, cognitive impairment, severity of PD symptoms, sleep disorders (somnolence), and visual disorders [<xref ref-type="bibr" rid="B75">74</xref>]. Risk of psychotic symptoms is increased in late onset PD, in patients taking high doses of dopaminergic drugs and suffering of REM sleep behaviour disorder (RBD). Hallucinations must be identified by systematically questioning the patient.</p><p>Visual hallucinations are surprising, but their intensity is quite variable. Benign hallucinations are limited to presence sensation, passing lights or visions at periphery of the visual field, with great tolerance by the patient. Conversely, elaborated hallucinations are usually disabling because their disturbing nature (wild animals, fantastic human creatures). Illusions consist of transformation of a real image and occur more often in the dark. Auditive, olfactive, or tactile hallucinations are less frequent [<xref ref-type="bibr" rid="B74">73</xref>]. Visual perception disorders and poor visual discrimination are often associated with hallucinations [<xref ref-type="bibr" rid="B76">75</xref>]. In 10 parkinsonian patients with severe hallucinations, hallucinations occurred with the irruption of periods of REM sleep during the day [<xref ref-type="bibr" rid="B77">76</xref>].</p><p>Hallucinations may occur in the presence of delusions with delirious convictions and can cause significant distress to the patients and their surroundings. Hallucinations are not recognized by the patient when alterations of cognitive faculties or dementia are also present. This cognitive decline plays a role in chronic evolution of hallucinations. Hallucination episode can even lead to the institutionalisation of an aged patient. Hallucinations are a risk factor for the development of cognitive impairment and dementia [<xref ref-type="bibr" rid="B78">77</xref>]. This association with increased disability and dementia place PD psychosis within symptoms signalling a serious disease course [<xref ref-type="bibr" rid="B73">72</xref>, <xref ref-type="bibr" rid="B79">78</xref>].</p><p>Despite hallucinations can be present in drug-naïve patients, they are mostly induced by dopaminergic therapies, especially dopamine agonists, but there is no simple dose-effect relationship between dopaminergic therapy and hallucinations [<xref ref-type="bibr" rid="B80">79</xref>]. Improvement of hallucinations follows the decrease of dopaminergic treatment. </p><p>In addition to the iatrogenic hypothesis, it is now admitted that specific factors linked to the disease may contribute to hallucinations. Hallucinations could be related to hypersensitization of dopamine receptors in frontal and limbic areas. Studies with functional MRI (fMRI) have confirmed the role of visual associative cortical areas, with dysfunction of networks between these areas and frontal lobes, on one hand, and subcortical areas, one the other hand [<xref ref-type="bibr" rid="B81">80</xref>]. Lesions in the pedunculopontine nucleus, locus cœruleus, dopaminergic raphe nucleus, lingual gyrus, and superior parietal lobe are also implicated in the pathophysiology of hallucinations [<xref ref-type="bibr" rid="B82">81</xref>]. Moreover, accumulation of Lewy bodies in amygdala, parahippocampal cortex, and inferior parietal cortex is described in case of hallucinations [<xref ref-type="bibr" rid="B83">82</xref>]. </p><p>Treatment of hallucinations often necessitates reducing the dopaminergic treatment, despite the risk of recrudescence of the motor parkinsonian symptoms (increase of akinesia). Most of the time, the treatment implies a combination of strategies addressing the possible contributing factors in individual cases (infection, metabolic disturbances, etc.). All pharmacological treatment must be revised and adjusted if they are believed to contribute to the symptomatology, especially the antidepressants, anxiolytic, anticholinergic, and benzodiazepines. Small doses of atypical antipsychotics may be used. In practice, clozapine remains the most recommended treatment [<xref ref-type="bibr" rid="B84">83</xref>].</p></sec><sec id="sec2.5"><title>2.5. Pain</title><p>Pain is the more frequent NMS at onset of the disease, and its prevalence increases with the duration of disease [<xref ref-type="bibr" rid="B85">84</xref>, <xref ref-type="bibr" rid="B86">85</xref>]. Pain may precede the onset of motor parkinsonian symptoms. The prevalence of all types of pain is high, but variably assessed. In a recent case-control study [<xref ref-type="bibr" rid="B87">86</xref>], the frequency of pain was greater in PD patients (69.9%) than in controls (62.8%). After adjustment concerning osteo-articular comorbidity, pain is estimated to be twice more frequent in PD patients than in patients without PD [<xref ref-type="bibr" rid="B88">87</xref>]. Chronic pain is present in 30% to 85% of patients [<xref ref-type="bibr" rid="B88">87</xref>]. Pain is directly attributed to PD in 46% of patients [<xref ref-type="bibr" rid="B89">88</xref>].</p><p>Clinical features of pain, prevalence, pathophysiology, and management of pain are well summarized in a review published by Ha and Jankovic, in 2011 (<xref ref-type="table" rid="tab2">Table 2</xref>) [<xref ref-type="bibr" rid="B92">89</xref>]. A common type of pain is musculoskeletal pain, resulting from a combination of factors such as rigidity, arthralgic pain, skeletal deformity, and mechanical factors [<xref ref-type="bibr" rid="B90">90</xref>]. Dystonic and nondystonic pains are both considered nonmotor features in PD [<xref ref-type="bibr" rid="B87">86</xref>]. Dystonic pain is reported in 40% of patients [<xref ref-type="bibr" rid="B91">91</xref>] and is dopa responsive. Therefore, painful spasms typically involving feet (such as “off” medication dystonia, or early morning dystonia) are improved by adaptation of levodopatherapy. In PD, nondystonic types of pain include arthralgic, cramping, peripheral neuropathic pain, and central neuropathic pain (burning, tingling, formication, or bizarre quality). Radicular or neuropathic pains are less frequent. Central neuropathic pain is poorly localized, constant, boring, ineffable, and not limited to a dermatome or nerve distribution [<xref ref-type="bibr" rid="B91">91</xref>]. Pain is a troublesome symptom, but often not recognized and not adequately treated. </p><p>Pathophysiology of pain involves the corticobasal ganglia-thalamic circuits for multisensory integration of pain. Dopaminergic nigrostriatal lesion leads to modification of pain perception. In PD, central pain modulation process is altered, with predominant hyper activation of nociceptive median circuit (affective component of pain). Nociceptive threshold is decreased in PD [<xref ref-type="bibr" rid="B93">92</xref>] but is in partly normalized by levodopa. In fact, levodopa changes the pain thresholds [<xref ref-type="bibr" rid="B94">93</xref>]. </p><p>Treatment of pain depends on the type of pain and usually requires a multidisciplinary approach. Not only levodopa-related dystonia, but also other types of pain (musculoskeletal pain related to rigidity and akinesia, akathisia), respond to optimization of levodopatherapy. Pain responds frequently to dopaminergic medication also; reduction of pulsatile dopamine receptors stimulation improves pain like levodopa-related dystonia, but also musculoskeletal pain. Botulinum toxin is used for treatment of focal painful dystonia [<xref ref-type="bibr" rid="B90">90</xref>]. Other neurotransmitters may also contribute to pain in PD, such as noradrenalin, serotonin, glutamate transmission and opioïd systems [<xref ref-type="bibr" rid="B95">94</xref>]. The benefit of doluxetine (inhibitor of noradrenalin and serotonin) on primary pain symptoms in PD is an example of this involvement of other neurotransmitters [<xref ref-type="bibr" rid="B96">95</xref>].</p></sec><sec id="sec2.6"><title>2.6. Sleep Disorders</title><p>Sleep disorders are present in about 66% to 90% of PD patients. Sleep disorders are more frequent in subjects suffering from advanced disease. In PD, sleep disorders are multiple and have varied substratum. RBD is a substantial risk factor for development of PD and occurs in one third of patients with PD. </p><p>Nocturnal disturbances can be defined by three types as follows. <list list-type="alpha-lower"><list-item><p>PD-related motor symptoms, including nocturnal akinesia, early morning dystonia, painful cramps, tremor, and difficulty turning in bed. The optimization of dopatherapy and use of long acting agonist is useful.</p></list-item><list-item><p>Nocturnal behavioural disturbances (agitation, confusion) related to the presence and/or the treatment of PD psychiatric symptoms (hallucinations, depression, and anxiety). Adjustment of the drugs that may induce these disturbances, treatment of depression and anxiety, prevention of confusion in patient with cognitive impairment and specific treatments should be used for each patient, according to the type of sleep disorder. </p></list-item><list-item><p>Other sleep disorders: insomnia (fragmentation of sleep) (37%), RBD (30%), restless legs syndrome (RLS) (15%), periodic movements of limbs during sleep (PMLS), and excessive day time sleepiness (EDS) (21%) [<xref ref-type="bibr" rid="B97">96</xref>].</p></list-item></list></p><p>Insomnia consists of difficulty falling asleep, with fragmentation of sleep and frequent awakenings and early awakening in the morning. The prevalence of insomnia in PD patients is from 40% to 80%. Motor disability plays a major role, particularly persistence of motor PD symptoms, akinesia (difficulties to turn in bed), rigidity, muscular contractures, dystonia (early morning dystonia), and pain linked to “off” periods. Others reasons for insomnia are nocturnal urinary disturbances (nocturia), RLS, and respiratory disorders. Effectively, 20% of PD patients are suffering from obstructive sleep apnea syndrome or SAS [<xref ref-type="bibr" rid="B98">97</xref>]. Excluding aging, main risk factors for insomnia are presence of depression or anxiety, duration of levodopatherapy, and duration of the disease. </p><p>In PD, abnormal movements during sleep can be single (such as myoclonia) or complex (such as RLS and PMLS). They can lead to frequent awakenings. PMLS are rhythmic movements with extension of big toe or flexion of ankle and knee. They are present in 15% of cases and are improved by levodopa. RLS (20% of PD patients) consists in a disabling sensation, deeply in legs, with urge to move, and with transitory decrease of these discomfort after moving [<xref ref-type="bibr" rid="B99">98</xref>]. RLS explains falling asleep difficulties and is often associated with PMLS. RLS is improved by slight dose of dopaminergic treatment in the evening. Nocturnal akathisia is associated with sensation of impatience, with difficulty to stay motionless. </p><p>RBD (from 25 to 50% of patients) is associated with loss of atonia (normal muscle tonus suppression) during REM sleep, with direct access to dream content and with acting out of the dream while asleep. A motor and verbal expression of dreams, with violent dream-enacting behaviors, happens in the absence of motor PD symptoms. Hence, a complex body language appears, pointed to a goal, nonstereotyped, with rapid and saccadic movements and risk of injuries or falls. RBD is equivalent to an active dream. One third to half of PD patients present RBD, often in association with hallucinations in a given patient. In PD, the presence of RBD is a risk factor for hallucinations and dementia. RBD is present in one-half of cases, before the onset of motor symptoms of PD. The presence of RBD is predictive factor of PD; from 20 to 40% of patents develop neurodegenerative disease (synucleinopathy) within a mean 5 years [<xref ref-type="bibr" rid="B100">99</xref>, <xref ref-type="bibr" rid="B101">100</xref>].</p><p>Parasomnias are undesirable behaviours occurring exclusively during sleep or exaggerated by sleep. Parasomnias include vivid dreams, altered dream content, nightmares, night terrors, nocturnal vocalizations, RBD, nocturnal hallucinations, sleep talking, somnambulism, and panic attacks [<xref ref-type="bibr" rid="B102">101</xref>]. The most relevant parasomnias in PD are RBD and nocturnal hallucinations. Most parasomnias are few disabling, and the patient even does not know about it. This is not true for the bed partner, who witnesses these nocturnal disturbing behaviors and, then, constitutes a great informative source for the physicians. These phenomenona, particularly vivid dreams and hallucinations, can be amplified by levodopa. The clinician should pay attention to the occurrence of vivid dreams because it is the forewarning sign of hallucinations and levodopa-induced “psychosis.”</p><p>Excessive daytime somnolence (EDS) is defined as a symptomatic daytime somnolence with frequent sleep periods. The causal factors of EDS areinsomnia, depression, dysautonomia (nocturnal hyperhydrosis and nocturia), and some drug therapy. The frequency of EDS and sleep attacks is variably assessed according to studies, from 20% to 50% of patients [<xref ref-type="bibr" rid="B103">102</xref>]. EDS appears more frequently in advanced PD, associated with cognitive disorders or depression, long duration of levodopa therapy and hallucinations. Indeed, somnolence is at increased risk during levodopatherapy in vulnerable subjects such as aging patients with cognitive decline. EDS is linked to individual susceptibility in PD.</p><p>Abrupt sleep access, named “sleep attacks,” consists in abruptly transition between awakening and sleep state without prodrome. “Narcolepsy without cataplexy” is not infrequent in PD patient [<xref ref-type="bibr" rid="B77">76</xref>]; hallucinations coincide with access of diurnal REM sleep in PD patients presenting hallucinations and narcolepsy-like sleep disorder [<xref ref-type="bibr" rid="B100">99</xref>].</p><p>Dopamine agonists seem to increase the risk of EDS and “sleep attacks.” The clinicians must pay attention to the possibility of sleep attacks because the consequences can be very serious if they occur during driving.</p><p>The effects of dopaminergic treatment on insomnia are variable. Mostly, improvement of sleep follows an increase of levodopa dosage. However, too high or too late intake of dopaminergic therapy can promote insomnia. Sustained dopaminergic stimulation by the use of slow-release levodopa or long-acting dopaminergic agonists improves nocturnal akinesia and insomnia [<xref ref-type="bibr" rid="B104">103</xref>]. RBD can be treated by low dose of clonazepam. RLS is improved by low dosage of dopamine agonist, or opioids (codeine), or anticonvulsants (clonazepam) [<xref ref-type="bibr" rid="B105">104</xref>]. </p></sec><sec id="sec2.7"><title>2.7. Dysautonomia</title><p>Autonomic symptoms in PD include orthostatic hypotension, constipation, bladder and sexual dysfunction as well as sweating abnormalities [<xref ref-type="bibr" rid="B106">105</xref>]. Autonomic failure may be an early feature of PD although it is more typically associated with advanced stage of the disease. Prevalence of autonomic disturbances is variably assessed, ranging between 14% and 80%, and these symptoms are better evaluated with the SCOPA-AUT scale [<xref ref-type="bibr" rid="B107">106</xref>].</p><sec id="sec2.7.1"><title>2.7.1. Genitourinary Dysfunction</title><p>Lower urinary tract symptoms, such as urinary frequency, nocturia, and urinary incontinence, are frequent in PD, interesting one-half of patients, thereby affecting the quality of life. Urinary symptoms can appear early in the disease [<xref ref-type="bibr" rid="B8">8</xref>]. These symptoms are in relation to detrusor hyperactivity caused by an altered dopamine basal ganglia circuit, which normally inhibits the micturition reflex. Lower urinary tract symptoms increase with motor disability, possibly in relation to dopaminergic denervation. Anticholinergic agents for treatment of the detrusor hyperactivity must be cautiously used in PD [<xref ref-type="bibr" rid="B108">107</xref>].</p><p>Sexual dysfunction in PD is frequently reported, in one-half to two third of patients [<xref ref-type="bibr" rid="B109">108</xref>]. All the following aspects of sexual function can be altered: decrease of libido, decrease of sexual intercourse, decrease of orgasm, decrease of erection, and ejaculation. Hypothalamic dysfunction is mostly responsible for sexual dysfunction, in PD, via dopamine-oxytocin pathways, normally promoting libido and erection [<xref ref-type="bibr" rid="B108">107</xref>]. Among men with erectile at baseline, a retrospective study concludes to a 3.8-fold increase in risk of developing PD [<xref ref-type="bibr" rid="B110">109</xref>].</p></sec><sec id="sec2.7.2"><title>2.7.2. Orthostatic Hypotension in PD</title><p>Orthostatic hypotension is defined as a fall of at least 20 mm Hg fall in systolic pressure and/or 10 mm Hg fall in diastolic pressure within three minutes of standing [<xref ref-type="bibr" rid="B111">110</xref>]. Blood pressure should be measured after 15 minutes of supine rest, and thereafter every minute for five minutes while standing, with measurement of the heart rate [<xref ref-type="bibr" rid="B112">111</xref>]. There is an orthostatic hypotension in 20%–58% of PD patients [<xref ref-type="bibr" rid="B113">112</xref>]. PD is a cause of primary autonomic failure with presence of peripheral postganglionic sympathetic dysfunction, which can be demonstrated by MIBG cardiac scintigraphy [<xref ref-type="bibr" rid="B114">113</xref>]. Early onset of symptomatic orthostatic hypotension is considered as exclusion criteria for idiopathic PD [<xref ref-type="bibr" rid="B115">114</xref>]. Symptoms of autonomic dysfunction correlate with disease duration and severity. Additional risk factors are male sex, increased age, and large doses of levodopa [<xref ref-type="bibr" rid="B116">115</xref>]. Antiparkinsonian medications, such as levodopa, dopamine agonists, and I-MAO B, can induce orthostatic hypotension, independently of the disease.</p><p>Treatment of orthostatic hypotension related to PD consists systematically of nonpharmacological strategies (gradual stand-up, sleeping with head-up position, fragmentation of meals, avoidance of high carbohydrates or low sodium diet, large quantities of fluid intake, elastic stockings). Drugs acting on postsynaptic adrenoreceptors, inhibiting vasodilating factors, and acting on volemia have not been evaluated in PD and should be used only with respect of contraindications (supine arterial hypertension) and cardiovascular status [<xref ref-type="bibr" rid="B112">111</xref>].</p></sec><sec id="sec2.7.3"><title>2.7.3. Constipation</title><p>Constipation is more frequent in patients who subsequently develop PD than in control [<xref ref-type="bibr" rid="B117">116</xref>]. Precession of motor symptoms by constipation is demonstrated [<xref ref-type="bibr" rid="B118">117</xref>]. Disabling constipation (from 45% to 60% of PD patients) predominates on the later stage of disease, with difficulty in defecation and reduced number of bowel movements, in comparison with early stages [<xref ref-type="bibr" rid="B119">118</xref>].</p><p>Treatment of constipation is identical to other causes of constipation (increase dietary fibbers, avoid dehydration, increase exercise, and laxatives), but also requires adaptation of levodopatherapy in patients with motor fluctuations. </p></sec></sec></sec><sec id="sec3"><title>3. Nonmotor Fluctuations (NMFs)</title><p>NMFs are often underappreciated [<xref ref-type="bibr" rid="B120">119</xref>]. Motor fluctuations, in relation with decrease of dopamine striatal transmission, are characterized by the reemergence of parkinsonian motor symptoms during “off” state, such as the “wearing off” or the “on-off” phenomenon. NMSs occur in the “off” periods, as well as during “on” state. NMFs vary according to plasma dopaminergic concentrations, such as motor fluctuations. In fact, dopaminergic systems are involved, but other neurotransmitters could be interested, such as serotonin or noradrenalin, via modulation by dopaminergic pathways [<xref ref-type="bibr" rid="B121">120</xref>]. </p><p>NMFs are sometimes predominant (example, anxiety). They consist of autonomic disorders (blood pressure changes, urinary frequency and urgency, thermoregulation disorders), cognitive/psychiatric (anxiety, depression, and slowness of thinking), and sensory complaints (pain, fatigue, and akathisia) [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B122">121</xref>] (<xref ref-type="table" rid="tab3">Table 3</xref>).</p><p>In a study questioning 50 PD patients, Witjas and col conclude that all patients have at least one type of NMFs, and that more than one quarter are more disabling with NMFs than with motor fluctuations [<xref ref-type="bibr" rid="B5">5</xref>]. The most frequent NMF is anxiety (66%), then drenching sweats (64%), slowness of thinking (58%), fatigue (56%), akathisia (54%), irritability (52%), and hallucinations (49%). Autonomic symptoms consist of excessive sweating, swallowing difficulties, abdominal discomfort, urgency, or urinary frequency, in “off” periods. </p><sec id="sec3.1"><title>3.1. Diagnosis Tools for NMS</title><p>NMSs are frequently not accurately assessed in everyday clinical practice. The routine administration of screening tools, followed by a further detailed evaluation, could notably enhance the NMS identification.</p><p>Currently, the following instruments have been developed and are helpful in clinical practice.</p><p>(a) The NMSQuest (NMSQ), a self-administered screening tool, consists of 30 items, classified in 10 domains [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B124">123</xref>, <xref ref-type="bibr" rid="B125">124</xref>]. These domains are cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastrointestinal, urinary, sexual, and miscellaneous. The frequency of NMS, by reporting these with NMSQ, was assessed with clinical scales of specific NMS. The impact of NMS on quality of life was measured. In multivariate analysis, depression has the stronger association with health-related quality of life (Hr-QoL), followed by fatigue, thermoregulatory, gastrointestinal, and cardiovascular autonomic function (orthostatic hypotension), daytime somnolence, and urinary problems.</p><p>Autonomic dysfunction, psychiatric complications, pain, fatigue, and sleep problems are major correlates of poor Hr-QoL [<xref ref-type="bibr" rid="B126">125</xref>].</p><p>(b) The non-motor symptoms scale (NMSS), consisting in 30 items instrument, is rated by clinicians, to explore 9 domains (cardiovascular, sleep/fatigue, mood/apathy, perceptual problems/hallucinations, attention/memory, gastrointestinal, urinary, sexual dysfunction, and miscellaneous) [<xref ref-type="bibr" rid="B127">126</xref>]. Items are scored for frequency and severity. NMSS is specifically designed for the comprehensive assessment of NMS in patients with PD. Psychometric attributes of NMSS were confirmed by the study of Martinez-Martin et al. in 2009 [<xref ref-type="bibr" rid="B125">124</xref>]. There is a close association between NMSS and PDQ 39 [<xref ref-type="bibr" rid="B125">124</xref>], and a correlation between NMSS and NMSQ and PDQ8 [<xref ref-type="bibr" rid="B127">126</xref>]. </p><p>(c) The scales for outcomes in PD programmes (SCOPA) to address the unmet need of assessment tools for NMS in PD are validated for motor and nonmotor domains as follows: scale for outcome of PD-cognitive scale (SCOPA-COG) [<xref ref-type="bibr" rid="B128">127</xref>], scale for outcome of PD-sleep scale (SCOPA-Seep scale), and scale for outcome of PD-autonomic scale (SCOPA-AUT) [<xref ref-type="bibr" rid="B129">128</xref>, <xref ref-type="bibr" rid="B130">129</xref>]. An available patient reported daily diary for measurement of both fluctuating motor and non-motor PD symptoms which have been identified and validated: it consists in the “Revised SCOPA-Diary Card (Scales for outcomes of PD-Diary-Card”) [<xref ref-type="bibr" rid="B131">130</xref>].</p><p>(d) The following rating scales have been recommended by the Movement Disorder Society's Task Force on Rating Scales in Movement Disorders: </p><p>(i) Apathy Scale (AS);</p><p>(ii) Beck Depression Inventory (BDI); Geriatric Depression Scale (GDS), Hamilton Rating Scale for Depression (HAM-D), Hospital Anxiety and Depression Scale (HADS); </p><p>(iii) Montgomery Asberg Depression Rating Scale (MADRS); </p><p>(iv) SCOPA-AUT for assessment of autonomic disorders;</p><p>(v) Parkinson's disease Quality of Life Scale (PDQUALIF)</p><p>(vi) Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS): the Movement Disorders Society's revision of the UPDRS (MDS-UPDRS) is an improved scale, taking in count NMS symptoms. MDS-UPDRS includes mainly non motor domains [<xref ref-type="bibr" rid="B132">131</xref>]. Validation of the MDS-UPDRS Part 1 for non motor symptoms in Parkinson's disease has demonstrated a strong relationship with a composite score of validated scales for NMS aspects of PD [<xref ref-type="bibr" rid="B133">132</xref>].</p><p>(vii) Brief Psychiatric Rating Scale (BPRS); Neuropsychiatric Inventory (NPI); Positive and Negative Syndrome Scale for Schizophrenia (PANSS); Scale for the Assessment of Positive Symptoms (SAPS); and Scale for Assessment of Negative Symptoms (SANS).</p><p>(e) Nonmotor fluctuation assessment instrument (NoMoFA) is an instrument of assessment of on non motor fluctuations in PD [<xref ref-type="bibr" rid="B134">133</xref>]. NoMoFA is proposed as a patient-based instrument for detection of NMFs [<xref ref-type="bibr" rid="B134">133</xref>].</p><p>(f) A task force that has been commissioned by the Movement Disorders Society [<xref ref-type="bibr" rid="B135">134</xref>] recommended six scales for sleep assessment in PD: (a) the PD sleep scale (PDSS) and the Pittsburg sleep quality index (PSQI) for rating overall sleep problems; (b) the SCOPA-sleep (SCOPA) for rating overall sleep problems both to screen and to measure severity, and daytime sleepiness; (c) the Epworth sleepiness scale (ESS) for rating daytime sleepiness; (d) the inappropriate sleep composite score (ISCS), for sleepiness or sleep attacks; (e) the Stanford sleepiness scale (SSS; non validated) for rating sleepiness and measure severity at specific moment.</p><p>(g) Questionnaire for impulsive compulsive disorders (QUIP) is validated [<xref ref-type="bibr" rid="B136">135</xref>].</p></sec></sec><sec id="sec4"><title>4. Premotor NMS</title><p>Some NMS can be the earliest symptoms of PD [<xref ref-type="bibr" rid="B138">136</xref>, <xref ref-type="bibr" rid="B137">137</xref>], occuring in the premotor phase, that is, years before the development of akinesia, rigidity, or tremor. The identification of premotor NMS opens up the possibility of presymptomatic diagnosis of PD. Premotor NMS are olfactory dysfunction, dysautonomia, mood disorders, and sleep disorders (<xref ref-type="table" rid="tab4">Table 4</xref>).</p><p>Hyposmia or olfactory loss is a disorder of odour detection, identification, and/or discrimination, probably due to the alteration of olfactory bulb, anterior olfactory nerve, amygdala and perirhinal cortex. More than 90% of PD patients present hyposmia or anosmia. Association between impaired olfaction and future PD is proved. Olfactory dysfunction may predict and can be considered as an early marker of PD; patients affected by hyposmia present a 10% increased risk of developing PD within 2 years of the onset of olfactory dysfunction, compared to their asymptomatic relatives [<xref ref-type="bibr" rid="B139">138</xref>, <xref ref-type="bibr" rid="B140">139</xref>]. Olfactory loss can even predate the development of clinical PD by up to 4 years. Whatever hyposmia precedes or occurs simultaneously with neuronal loss of the substantia nigra requires clarification [<xref ref-type="bibr" rid="B140">139</xref>]. </p><p>Dysautonomia can also precede motor symptoms. In fact, constipation appears to be common in PD patients at onset of the disease and can antedate the development of parkinsonian symptoms by more than 10 to 18 years [<xref ref-type="bibr" rid="B118">117</xref>]. A recent study from the Mayo Clinic found an odds ratio of 2.48 for the presence of constipation preceding PD, with a lag time between the onset of constipation and motor symptoms of 7.9 years [<xref ref-type="bibr" rid="B142">140</xref>]. Constipation could be related to the underlying pathological process of PD, such as the deposition of alpha synuclein at the dorsal nucleus of the vagus and at the enteric plexus [<xref ref-type="bibr" rid="B143">141</xref>, <xref ref-type="bibr" rid="B144">142</xref>]. </p><p>Depression can predate PD diagnosis by 3 to 6 years before diagnosis [<xref ref-type="bibr" rid="B145">143</xref>]. It is estimated that depressed patients have a 2.2- to 3.2-fold higher risk for developing PD than nondepressed subjects [<xref ref-type="bibr" rid="B31">30</xref>], but depression is not predictive of future PD development.</p><p>Sleep disturbances are from 1.5 to 3.5 times more common in established PD than in healthy controls or patients with other chronic diseases [<xref ref-type="bibr" rid="B146">144</xref>, <xref ref-type="bibr" rid="B147">145</xref>]. Subjects with idiopathic RBD are at high risk of developing PD. In a study following 40 patients with idiopathic RBD, 19% to 38% have developed PD after 5-year followup [<xref ref-type="bibr" rid="B148">146</xref>]. In about 20% of PD patients with RBD, the reported onset of RBD antedates that of Parkinsonism (PD and parkinsonian syndromes) by several years [<xref ref-type="bibr" rid="B149">147</xref>]. About 20% of patients with idiopathic RBD, characterized by loss of normal atonia with REM sleep, will develop PD or dementia within 10 years [<xref ref-type="bibr" rid="B150">148</xref>]. Locus coeruleus and pedunculopontine nuclei lesions seem to be responsible for RBD in PD.</p><p>Relation between premotor symptoms and pathological process in PD is actually discussed. The theory of Braak staging [<xref ref-type="bibr" rid="B151">149</xref>] could explain extranigral early lesions. Alpha-synuclein pathology begins in the anterior olfactory nucleus and the lower brain stem (dorsal motor nucleus of the vagus) and spreads upward from the medulla, only affecting the substantia nigra compacta at Braak stage 3, and then purses an ascending course up to cortical areas. The pathology also affects the peripheral autonomic nervous system involving sympathetic ganglia, cardiac sympathetic afferents, and enteric nervous system [<xref ref-type="bibr" rid="B152">150</xref>].</p></sec><sec id="sec5"><title>5. Conclusion</title><p>With the NMSQuest, the prevalence of NMS is high. NMS are present across all disease stages and increase with duration and severity of the disease [<xref ref-type="bibr" rid="B124">123</xref>]. A study of prevalence of NMS in more than 1000 patients, using a semistructured interview, reveals that all patients complained of a range of NMS, across all stages of the disease [<xref ref-type="bibr" rid="B97">96</xref>]. </p><p> NMS are underestimated in contrast to motor symptoms. A range of NMSs are often undeclared, and treatments are inappropriate [<xref ref-type="bibr" rid="B153">151</xref>]. Depression, anxiety, and fatigue are not identified in one half of patients, sleep disorders in more than 40% [<xref ref-type="bibr" rid="B154">152</xref>]. Then, the importance to detect NMS appears because they are less known than motor disturbances, and not so well treated.</p><p>Indeed, during routine consultation, two errors must be avoided: (a) to take into account the clinical presentation at the moment of examination and not consider the condition of the patient in daily life; (b) to take into account only anamnesis and appearance of motor symptoms, and forget to look for NMS. The patient itself can be embarrassed to declare some NMS, such as ICDs or hallucinations.</p><p>Nonmotor symptoms are determinant for the quality of life of patients. The impact of NMS on quality of life can be evaluated with the aim of the NMSS: the most frequent complains are being nocturia (68%), fatigue (66%), and dribbling saliva (57%) [<xref ref-type="bibr" rid="B155">153</xref>]. Severity of the disease (Hoehn and Yahr stade >3) is associated with reduction of quality of life, increased disability, and increased NMS prevalence [<xref ref-type="bibr" rid="B156">154</xref>]. Depression has leave the impact of motor signs on quality of life. Anxiety and other non motor symptoms are also important separate determinants of poor health status in PD [<xref ref-type="bibr" rid="B157">155</xref>]. PD patients with cognitive dysfunction are at risk for deterioration of quality of life over time [<xref ref-type="bibr" rid="B158">156</xref>]. At advanced stage of the disease, the treatment of NMS should improve the quality of life [<xref ref-type="bibr" rid="B159">157</xref>].</p></sec></body><back><ack><title>Conflicts of Interests</title><p> The authors declare that there is no conflict of interests.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>KR</given-names></name><name><surname>Healy</surname><given-names>D</given-names></name><name><surname>Shapira</surname><given-names>AHV</given-names></name></person-group><article-title>The non motor symptoms of Parkinson’s disease NMS Quest. Diagnosis and management</article-title><source><italic>The Lancet Neurology</italic></source><year>2006</year><volume>5</volume><fpage>235</fpage><lpage>245</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><name><surname>Rodriguez-Blazquez</surname><given-names>C</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2009</year><volume>73</volume><issue>19</issue><fpage>1584</fpage><lpage>1591</lpage><pub-id pub-id-type="other">2-s2.0-72049092374</pub-id><pub-id pub-id-type="pmid">19901251</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>KR</given-names></name><name><surname>Odin</surname><given-names>P</given-names></name><name><surname>Antonini</surname><given-names>A</given-names></name><name><surname>Martinez-Martin</surname><given-names>P</given-names></name></person-group><article-title>Parkinson’s disease: the non-motor issues</article-title><source><italic>Parkinsonism and Related Disorders</italic></source><year>2011</year><volume>17</volume><issue>10</issue><fpage>717</fpage><lpage>723</lpage><pub-id pub-id-type="other">2-s2.0-79959914850</pub-id><pub-id pub-id-type="pmid">21741874</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosset</surname><given-names>D</given-names></name><name><surname>Taurah</surname><given-names>L</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis</article-title><source><italic>Journal of Neurology, Neurosurgery and Psychiatry</italic></source><year>2007</year><volume>78</volume><issue>5</issue><fpage>465</fpage><lpage>469</lpage><pub-id pub-id-type="other">2-s2.0-34247238285</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Gaig</surname><given-names>C</given-names></name><name><surname>Santamaría</surname><given-names>J</given-names></name><name><surname>Compta</surname><given-names>Y</given-names></name></person-group><article-title>Diagnosis and the premotor phase of Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2009</year><volume>72</volume><issue>7, supplement 2</issue><fpage>S12</fpage><lpage>S20</lpage><pub-id pub-id-type="other">2-s2.0-61949235512</pub-id><pub-id pub-id-type="pmid">19221308</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witjas</surname><given-names>T</given-names></name><name><surname>Kaphan</surname><given-names>E</given-names></name><name><surname>Azulay</surname><given-names>JP</given-names></name><etal></etal></person-group><article-title>Nonmotor fluctuations in Parkinson’s disease: frequent and disabling</article-title><source><italic>Neurology</italic></source><year>2002</year><volume>59</volume><issue>3</issue><fpage>408</fpage><lpage>413</lpage><pub-id pub-id-type="other">2-s2.0-0037072288</pub-id><pub-id pub-id-type="pmid">12177375</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barone</surname><given-names>P</given-names></name><name><surname>Antonini</surname><given-names>A</given-names></name><name><surname>Colosimo</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2009</year><volume>24</volume><issue>11</issue><fpage>1641</fpage><lpage>1649</lpage><pub-id pub-id-type="other">2-s2.0-69949153066</pub-id><pub-id pub-id-type="pmid">19514014</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Sullivan</surname><given-names>SS</given-names></name><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>Gallagher</surname><given-names>DA</given-names></name><name><surname>Massey</surname><given-names>LA</given-names></name><name><surname>Silveira-Moriyama</surname><given-names>L</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study</article-title><source><italic>Movement Disorders</italic></source><year>2008</year><volume>23</volume><issue>1</issue><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="other">2-s2.0-39549095825</pub-id><pub-id pub-id-type="pmid">17994582</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>LM</given-names></name><name><surname>Taback</surname><given-names>RL</given-names></name><name><surname>Bean</surname><given-names>J</given-names></name><name><surname>Weiner</surname><given-names>WJ</given-names></name></person-group><article-title>Comorbity of the nonmotor symptoms of Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2001</year><volume>16</volume><issue>3</issue><fpage>507</fpage><lpage>510</lpage><pub-id pub-id-type="other">2-s2.0-0035353726</pub-id><pub-id pub-id-type="pmid">11391746</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><name><surname>Shapira</surname><given-names>AHV</given-names></name><name><surname>Stocchi</surname><given-names>F</given-names></name></person-group><article-title>Prevalence of non motor symptoms in Parkinson’s disease in an international setting; study using non-motor symptoms questionnaire in 545 patients</article-title><source><italic>Movement Disorders</italic></source><year>2007</year><volume>22</volume><fpage>1623</fpage><lpage>1629</lpage><pub-id pub-id-type="pmid">17546669</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolters</surname><given-names>EC</given-names></name></person-group><article-title>Non-motor extranigral signs and symptoms in Parkinson’s disease</article-title><source><italic>Parkinsonism and Related Disorders</italic></source><year>2009</year><volume>15</volume><issue>3</issue><fpage>S6</fpage><lpage>S12</lpage><pub-id pub-id-type="other">2-s2.0-72149091508</pub-id><pub-id pub-id-type="pmid">20083010</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remy</surname><given-names>P</given-names></name><name><surname>Doder</surname><given-names>M</given-names></name><name><surname>Lees</surname><given-names>A</given-names></name><name><surname>Turjanski</surname><given-names>N</given-names></name><name><surname>Brooks</surname><given-names>D</given-names></name></person-group><article-title>Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system</article-title><source><italic>Brain</italic></source><year>2005</year><volume>128</volume><issue>6</issue><fpage>1314</fpage><lpage>1322</lpage><pub-id pub-id-type="other">2-s2.0-20444477480</pub-id><pub-id pub-id-type="pmid">15716302</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>KR</given-names></name><name><surname>Schapira</surname><given-names>AH</given-names></name></person-group><article-title>Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment</article-title><source><italic>The Lancet Neurology</italic></source><year>2009</year><volume>8</volume><issue>5</issue><fpage>464</fpage><lpage>474</lpage><pub-id pub-id-type="other">2-s2.0-64349083816</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thobois</surname><given-names>S</given-names></name><name><surname>Ardouin</surname><given-names>C</given-names></name><name><surname>Schmitt</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Behavioral disorders in Parkinson’s disease: from pathophysiology to the mastery of dopaminergic treatment</article-title><source><italic>Revue Neurologique</italic></source><year>2010</year><volume>166</volume><issue>10</issue><fpage>816</fpage><lpage>821</lpage><pub-id pub-id-type="other">2-s2.0-77957227728</pub-id><pub-id pub-id-type="pmid">20739041</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voon</surname><given-names>V</given-names></name><name><surname>Fernagut</surname><given-names>PO</given-names></name><name><surname>Wickens</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders</article-title><source><italic>The Lancet Neurology</italic></source><year>2009</year><volume>8</volume><issue>12</issue><fpage>1140</fpage><lpage>1149</lpage><pub-id pub-id-type="other">2-s2.0-72149094883</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrag</surname><given-names>A</given-names></name><name><surname>Jahanshahi</surname><given-names>M</given-names></name><name><surname>Quinn</surname><given-names>N</given-names></name></person-group><article-title>How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population</article-title><source><italic>Movement Disorders</italic></source><year>2000</year><volume>15</volume><fpage>1112</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">11104193</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>KR</given-names></name><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>RG</given-names></name><etal></etal></person-group><article-title>The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study</article-title><source><italic>Movement Disorders</italic></source><year>2007</year><volume>22</volume><issue>13</issue><fpage>1901</fpage><lpage>1911</lpage><pub-id pub-id-type="other">2-s2.0-36248998208</pub-id><pub-id pub-id-type="pmid">17674410</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><name><surname>Rodriguez-Blazquez</surname><given-names>C</given-names></name><name><surname>Kurtis</surname><given-names>MM</given-names></name><name><surname>Chaudhuri</surname><given-names>KR</given-names></name></person-group><article-title>The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2011</year><volume>26</volume><issue>3</issue><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="other">2-s2.0-79953276342</pub-id><pub-id pub-id-type="pmid">21264941</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Coelho</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2011</year><volume>26</volume><issue>3</issue><fpage>S42</fpage><lpage>S80</lpage><pub-id pub-id-type="pmid">22021174</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tom</surname><given-names>T</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name></person-group><article-title>Depression in Parkinson’s disease. Pharmacological characteristics and treatment</article-title><source><italic>Drugs and Aging</italic></source><year>1998</year><volume>12</volume><issue>1</issue><fpage>55</fpage><lpage>74</lpage><pub-id pub-id-type="other">2-s2.0-0031983225</pub-id><pub-id pub-id-type="pmid">9467687</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravina</surname><given-names>B</given-names></name><name><surname>Camicioli</surname><given-names>R</given-names></name><name><surname>Como</surname><given-names>PG</given-names></name><etal></etal></person-group><article-title>The impact of depressive symptoms in early Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2007</year><volume>69</volume><issue>4</issue><fpage>342</fpage><lpage>347</lpage><pub-id pub-id-type="other">2-s2.0-34547639700</pub-id><pub-id pub-id-type="pmid">17581943</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JL</given-names></name></person-group><article-title>Depression and Parkinson’s disease: a review</article-title><source><italic>American Journal of Psychiatry</italic></source><year>1992</year><volume>149</volume><issue>4</issue><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="other">2-s2.0-0026582759</pub-id><pub-id pub-id-type="pmid">1372794</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reijnders</surname><given-names>JSAM</given-names></name><name><surname>Ehrt</surname><given-names>U</given-names></name><name><surname>Weber</surname><given-names>WEJ</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Leentjens</surname><given-names>AFG</given-names></name></person-group><article-title>A systematic review of prevalence studies of depression in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2008</year><volume>23</volume><issue>2</issue><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="other">2-s2.0-39749146383</pub-id><pub-id pub-id-type="pmid">17987654</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>LCS</given-names></name></person-group><article-title>Mood disorders in Parkinson’s disease</article-title><source><italic>Parkinsonism & Related Disorders</italic></source><year>2012</year><volume>18, supplement 1</volume><fpage>S74</fpage><lpage>S76</lpage><pub-id pub-id-type="pmid">22166461</pub-id></element-citation></ref><ref id="B26"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devos</surname><given-names>D</given-names></name><name><surname>Dujardin</surname><given-names>K</given-names></name><name><surname>Poirot</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study</article-title><source><italic>Movement Disorders</italic></source><year>2008</year><volume>23</volume><issue>6</issue><fpage>850</fpage><lpage>857</lpage><pub-id pub-id-type="other">2-s2.0-48649084162</pub-id><pub-id pub-id-type="pmid">18311826</pub-id></element-citation></ref><ref id="B27"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menza</surname><given-names>M</given-names></name><name><surname>Dobkin</surname><given-names>RD</given-names></name><name><surname>Marin</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>A controlled trial of antidepressants in patients with Parkinson disease and depression</article-title><source><italic>Neurology</italic></source><year>2009</year><volume>72</volume><issue>10</issue><fpage>886</fpage><lpage>892</lpage><pub-id pub-id-type="other">2-s2.0-64049105010</pub-id><pub-id pub-id-type="pmid">19092112</pub-id></element-citation></ref><ref id="B28"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobkin</surname><given-names>RD</given-names></name><name><surname>Menza</surname><given-names>M</given-names></name><name><surname>Bienfait</surname><given-names>KL</given-names></name><etal></etal></person-group><article-title>Depression in Parkinson’s disease: symptom improvement and residual symptoms after acute pharmacologic management</article-title><source><italic>American Journal of Geriatric Psychiatry</italic></source><year>2011</year><volume>19</volume><issue>3</issue><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="other">2-s2.0-79952102384</pub-id><pub-id pub-id-type="pmid">20808132</pub-id></element-citation></ref><ref id="B29"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>L</given-names></name></person-group><article-title>Anxiety disorders in Parkinson’s disease</article-title><source><italic>International Review of Psychiatry</italic></source><year>2000</year><volume>12</volume><issue>4</issue><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="other">2-s2.0-0033637550</pub-id></element-citation></ref><ref id="B30"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuti</surname><given-names>A</given-names></name><name><surname>Ceravolo</surname><given-names>R</given-names></name><name><surname>Piccini</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Psychiatric comorbidity in a population of Parkinson’s disease patients</article-title><source><italic>European Journal of Neurology</italic></source><year>2004</year><volume>11</volume><issue>5</issue><fpage>315</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">15142224</pub-id></element-citation></ref><ref id="B31"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leentjens</surname><given-names>AF</given-names></name><name><surname>Dujardin</surname><given-names>K</given-names></name><name><surname>Marsh</surname><given-names>L</given-names></name><name><surname>Richard</surname><given-names>IH</given-names></name><name><surname>Starkstein</surname><given-names>SE</given-names></name><name><surname>Martinez-Martin</surname><given-names>P</given-names></name></person-group><article-title>Anxiety rating scales in Parkinson’s disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale</article-title><source><italic>Movement Disorders</italic></source><year>2011</year><volume>26</volume><issue>3</issue><fpage>407</fpage><lpage>415</lpage><pub-id pub-id-type="other">2-s2.0-79953281750</pub-id><pub-id pub-id-type="pmid">21384425</pub-id></element-citation></ref><ref id="B32"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leentjens</surname><given-names>AFG</given-names></name><name><surname>Dujardin</surname><given-names>K</given-names></name><name><surname>Marsh</surname><given-names>L</given-names></name><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><name><surname>Richard</surname><given-names>IH</given-names></name><name><surname>Starkstein</surname><given-names>SE</given-names></name></person-group><article-title>Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study</article-title><source><italic>Movement Disorders</italic></source><year>2011</year><volume>26</volume><issue>3</issue><fpage>484</fpage><lpage>492</lpage><pub-id pub-id-type="other">2-s2.0-79953267237</pub-id><pub-id pub-id-type="pmid">21312281</pub-id></element-citation></ref><ref id="B33"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belzer</surname><given-names>K</given-names></name><name><surname>Schneier</surname><given-names>FR</given-names></name></person-group><article-title>Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment</article-title><source><italic>Journal of Psychiatric Practice</italic></source><year>2004</year><volume>10</volume><issue>5</issue><fpage>296</fpage><lpage>306</lpage><pub-id pub-id-type="other">2-s2.0-4644237053</pub-id><pub-id pub-id-type="pmid">15361744</pub-id></element-citation></ref><ref id="B34"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>RG</given-names></name></person-group><article-title>Depression and anxiety subtypes in PD</article-title><source><italic>Journal of Neurology, Neurosurgery & Psychiatry</italic></source><year>2011</year><volume>82</volume><issue>7</issue><fpage>803</fpage><lpage>809</lpage></element-citation></ref><ref id="B35"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Stern</surname><given-names>MB</given-names></name><name><surname>Sethi</surname><given-names>K</given-names></name></person-group><article-title>The scientific and clinical basis for the treatment of Parkinson disease (2009)</article-title><source><italic>Neurology</italic></source><year>2009</year><volume>72</volume><issue>21, supplement 4</issue><fpage>S1</fpage><lpage>S136</lpage><pub-id pub-id-type="other">2-s2.0-66949117423</pub-id><pub-id pub-id-type="pmid">19470958</pub-id></element-citation></ref><ref id="B36"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin</surname><given-names>RS</given-names></name></person-group><article-title>Apathy: a neuropsychiatric syndrome</article-title><source><italic>Journal of Neuropsychiatry and Clinical Neurosciences</italic></source><year>1991</year><volume>3</volume><issue>3</issue><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="other">2-s2.0-0025899466</pub-id><pub-id pub-id-type="pmid">1821241</pub-id></element-citation></ref><ref id="B37"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starkstein</surname><given-names>SE</given-names></name><name><surname>Leentjens</surname><given-names>AFG</given-names></name></person-group><article-title>The nosological position of apathy in clinical practice</article-title><source><italic>Journal of Neurology, Neurosurgery and Psychiatry</italic></source><year>2008</year><volume>79</volume><issue>10</issue><fpage>1088</fpage><lpage>1092</lpage><pub-id pub-id-type="other">2-s2.0-53149124795</pub-id></element-citation></ref><ref id="B38"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starkstein</surname><given-names>SE</given-names></name><name><surname>Mayberg</surname><given-names>HS</given-names></name><name><surname>Preziosi</surname><given-names>TJ</given-names></name><name><surname>Andrezejewski</surname><given-names>P</given-names></name><name><surname>Leiguarda</surname><given-names>R</given-names></name><name><surname>Robinson</surname><given-names>RG</given-names></name></person-group><article-title>Reliability, validity, and clinical correlates of apathy in Parkinson’s disease</article-title><source><italic>Journal of Neuropsychiatry and Clinical Neurosciences</italic></source><year>1992</year><volume>4</volume><issue>2</issue><fpage>134</fpage><lpage>139</lpage><pub-id pub-id-type="other">2-s2.0-0026569057</pub-id><pub-id pub-id-type="pmid">1627973</pub-id></element-citation></ref><ref id="B39"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sockeel</surname><given-names>P</given-names></name><name><surname>Dujardin</surname><given-names>K</given-names></name><name><surname>Devos</surname><given-names>D</given-names></name><name><surname>Denève</surname><given-names>C</given-names></name><name><surname>Destée</surname><given-names>A</given-names></name><name><surname>Defebvre</surname><given-names>L</given-names></name></person-group><article-title>The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease</article-title><source><italic>Journal of Neurology, Neurosurgery and Psychiatry</italic></source><year>2006</year><volume>77</volume><issue>5</issue><fpage>579</fpage><lpage>584</lpage><pub-id pub-id-type="other">2-s2.0-33646897697</pub-id></element-citation></ref><ref id="B40"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benito-León</surname><given-names>J</given-names></name><name><surname>Cubo</surname><given-names>E</given-names></name><name><surname>Coronell</surname><given-names>C</given-names></name></person-group><article-title>Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study</article-title><source><italic>Movement Disorders</italic></source><year>2012</year><volume>27</volume><issue>2</issue><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="other">2-s2.0-79960464295</pub-id><pub-id pub-id-type="pmid">21780179</pub-id></element-citation></ref><ref id="B41"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>R</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name></person-group><article-title>Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits</article-title><source><italic>Cerebral Cortex</italic></source><year>2006</year><volume>16</volume><issue>7</issue><fpage>916</fpage><lpage>928</lpage><pub-id pub-id-type="other">2-s2.0-33745595886</pub-id><pub-id pub-id-type="pmid">16207933</pub-id></element-citation></ref><ref id="B42"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirsch-Darrow</surname><given-names>L</given-names></name><name><surname>Fernandez</surname><given-names>HF</given-names></name><name><surname>Marsiske</surname><given-names>M</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>Bowers</surname><given-names>D</given-names></name></person-group><article-title>Dissociating apathy and depression in Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2006</year><volume>67</volume><issue>1</issue><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="other">2-s2.0-33746853543</pub-id><pub-id pub-id-type="pmid">16832074</pub-id></element-citation></ref><ref id="B43"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thobois</surname><given-names>S</given-names></name><name><surname>Ardouin</surname><given-names>C</given-names></name><name><surname>Lhommée</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation</article-title><source><italic>Brain</italic></source><year>2010</year><volume>133</volume><issue>4</issue><fpage>1111</fpage><lpage>1127</lpage><pub-id pub-id-type="other">2-s2.0-77950817597</pub-id><pub-id pub-id-type="pmid">20237128</pub-id></element-citation></ref><ref id="B44"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czernecki</surname><given-names>V</given-names></name><name><surname>Pillon</surname><given-names>B</given-names></name><name><surname>Houeto</surname><given-names>JL</given-names></name><name><surname>Pochon</surname><given-names>JB</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name></person-group><article-title>Motivation, reward, and Parkinson’s disease: influence of dopatherapy</article-title><source><italic>Neuropsychologia</italic></source><year>2002</year><volume>40</volume><issue>13</issue><fpage>2257</fpage><lpage>2267</lpage><pub-id pub-id-type="other">2-s2.0-0036412603</pub-id><pub-id pub-id-type="pmid">12417456</pub-id></element-citation></ref><ref id="B45"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czernecki</surname><given-names>V</given-names></name><name><surname>Schüpbach</surname><given-names>M</given-names></name><name><surname>Yaici</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Apathy following subthalamic stimulation in parkinson disease: a dopamine responsive symptom</article-title><source><italic>Movement Disorders</italic></source><year>2008</year><volume>23</volume><issue>7</issue><fpage>964</fpage><lpage>969</lpage><pub-id pub-id-type="other">2-s2.0-49249084391</pub-id><pub-id pub-id-type="pmid">18398913</pub-id></element-citation></ref><ref id="B46"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin</surname><given-names>RS</given-names></name><name><surname>Fogel</surname><given-names>BS</given-names></name><name><surname>Hawkins</surname><given-names>J</given-names></name><name><surname>Duffy</surname><given-names>J</given-names></name><name><surname>Krupp</surname><given-names>B</given-names></name></person-group><article-title>Apathy: a treatable syndrome</article-title><source><italic>Journal of Neuropsychiatry and Clinical Neurosciences</italic></source><year>1995</year><volume>7</volume><issue>1</issue><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="other">2-s2.0-0028963416</pub-id><pub-id pub-id-type="pmid">7711487</pub-id></element-citation></ref><ref id="B47"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>D</given-names></name></person-group><article-title>Dopamine and impulse control disorders in Parkinson’s disease</article-title><source><italic>Annals of Neurology</italic></source><year>2008</year><volume>64</volume><issue>2, supplement</issue><fpage>S93</fpage><lpage>S100</lpage><pub-id pub-id-type="other">2-s2.0-58349083886</pub-id><pub-id pub-id-type="pmid">19127573</pub-id></element-citation></ref><ref id="B48"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Koester</surname><given-names>J</given-names></name><name><surname>Potenza</surname><given-names>MN</given-names></name><etal></etal></person-group><article-title>Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients</article-title><source><italic>Archives of Neurology</italic></source><year>2010</year><volume>67</volume><issue>5</issue><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="other">2-s2.0-77952157407</pub-id><pub-id pub-id-type="pmid">20457959</pub-id></element-citation></ref><ref id="B49"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>AH</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>Dopamine dysregulation syndrome in Parkinson’s disease</article-title><source><italic>Current Opinion in Neurology</italic></source><year>2004</year><volume>17</volume><issue>4</issue><fpage>493</fpage><lpage>398</lpage></element-citation></ref><ref id="B50"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voon</surname><given-names>V</given-names></name><name><surname>Fox</surname><given-names>SH</given-names></name></person-group><article-title>Medication-related impulse control and repetitive behaviors in Parkinson disease</article-title><source><italic>Archives of Neurology</italic></source><year>2007</year><volume>64</volume><issue>8</issue><fpage>1089</fpage><lpage>1096</lpage><pub-id pub-id-type="other">2-s2.0-34547862721</pub-id><pub-id pub-id-type="pmid">17698698</pub-id></element-citation></ref><ref id="B51"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pontone</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>JR</given-names></name><name><surname>Bassett</surname><given-names>SS</given-names></name><name><surname>Marsh</surname><given-names>L</given-names></name></person-group><article-title>Clinical features associated with impulse control disorders in Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2006</year><volume>67</volume><issue>7</issue><fpage>1258</fpage><lpage>1261</lpage><pub-id pub-id-type="other">2-s2.0-33749842780</pub-id><pub-id pub-id-type="pmid">17030761</pub-id></element-citation></ref><ref id="B52"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nirenberg</surname><given-names>MJ</given-names></name><name><surname>Waters</surname><given-names>C</given-names></name></person-group><article-title>Compulsive eating and weight gain related to dopamine agonist use</article-title><source><italic>Movement Disorders</italic></source><year>2006</year><volume>21</volume><issue>4</issue><fpage>524</fpage><lpage>529</lpage><pub-id pub-id-type="other">2-s2.0-33646233779</pub-id><pub-id pub-id-type="pmid">16261618</pub-id></element-citation></ref><ref id="B53"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyasaki</surname><given-names>JM</given-names></name><name><surname>Al Hassan</surname><given-names>K</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Voon</surname><given-names>V</given-names></name></person-group><article-title>Punding prevalence in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2007</year><volume>22</volume><issue>8</issue><fpage>1179</fpage><lpage>1181</lpage><pub-id pub-id-type="other">2-s2.0-34447507936</pub-id><pub-id pub-id-type="pmid">17230464</pub-id></element-citation></ref><ref id="B54"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>AJ</given-names></name><name><surname>Blackwell</surname><given-names>AD</given-names></name><name><surname>Barker</surname><given-names>RA</given-names></name><etal></etal></person-group><article-title>Predictors of punding in Parkinson’s disease: results from a questionnaire survey</article-title><source><italic>Movement Disorders</italic></source><year>2007</year><volume>22</volume><issue>16</issue><fpage>2339</fpage><lpage>2345</lpage><pub-id pub-id-type="other">2-s2.0-38549131256</pub-id><pub-id pub-id-type="pmid">17914729</pub-id></element-citation></ref><ref id="B55"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Siderowf</surname><given-names>AD</given-names></name><name><surname>Potenza</surname><given-names>MN</given-names></name><etal></etal></person-group><article-title>Association of dopamine agonist use with impulse control disorders in Parkinson disease</article-title><source><italic>Archives of Neurology</italic></source><year>2006</year><volume>63</volume><issue>7</issue><fpage>969</fpage><lpage>973</lpage><pub-id pub-id-type="other">2-s2.0-33745823166</pub-id><pub-id pub-id-type="pmid">16831966</pub-id></element-citation></ref><ref id="B56"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voon</surname><given-names>V</given-names></name><name><surname>Mehta</surname><given-names>AR</given-names></name><name><surname>Hallett</surname><given-names>M</given-names></name></person-group><article-title>Impulse control disorders in Parkinson’s disease: recent advances</article-title><source><italic>Current Opinion in Neurology</italic></source><year>2011</year><volume>24</volume><issue>4</issue><fpage>324</fpage><lpage>330</lpage><pub-id pub-id-type="other">2-s2.0-79960785470</pub-id><pub-id pub-id-type="pmid">21725242</pub-id></element-citation></ref><ref id="B57"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voon</surname><given-names>V</given-names></name><name><surname>Sohr</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><etal></etal></person-group><article-title>Impulse control disorders in Parkinson’s disease: a multicentrer case-control study</article-title><source><italic>Annals of Neurology</italic></source><year>2011</year><volume>69</volume><issue>6</issue><fpage>986</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">21416496</pub-id></element-citation></ref><ref id="B58"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Stewart</surname><given-names>S</given-names></name><name><surname>Shea</surname><given-names>JA</given-names></name><etal></etal></person-group><article-title>Validation of the questionnaire for impulsive-compulsive behaviors in Parkinson’s disease (QUIP)</article-title><source><italic>Movement Disorders</italic></source><year>2009</year><volume>24</volume><fpage>1461</fpage><lpage>1467</lpage><pub-id pub-id-type="pmid">19452562</pub-id></element-citation></ref><ref id="B59"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardouin</surname><given-names>C</given-names></name><name><surname>Chéreau</surname><given-names>I</given-names></name><name><surname>Llorca</surname><given-names>PM</given-names></name><etal></etal></person-group><article-title>Assessment of hyper- and hypodopaminergic behaviors in Parkinson’s disease</article-title><source><italic>Revue Neurologique</italic></source><year>2009</year><volume>165</volume><issue>11</issue><fpage>845</fpage><lpage>856</lpage><pub-id pub-id-type="other">2-s2.0-70350712268</pub-id><pub-id pub-id-type="pmid">19683776</pub-id></element-citation></ref><ref id="B60"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cilia</surname><given-names>R</given-names></name><name><surname>Siri</surname><given-names>C</given-names></name><name><surname>Marotta</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Functional abnormalities underlying pathological gambling in parkinson disease</article-title><source><italic>Archives of Neurology</italic></source><year>2008</year><volume>65</volume><issue>12</issue><fpage>1604</fpage><lpage>1611</lpage><pub-id pub-id-type="other">2-s2.0-61449212993</pub-id><pub-id pub-id-type="pmid">19064747</pub-id></element-citation></ref><ref id="B61"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Eimeren</surname><given-names>T</given-names></name><name><surname>Pellecchia</surname><given-names>G</given-names></name><name><surname>Cilia</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD</article-title><source><italic>Neurology</italic></source><year>2010</year><volume>75</volume><issue>19</issue><fpage>1711</fpage><lpage>1716</lpage><pub-id pub-id-type="other">2-s2.0-78649506636</pub-id><pub-id pub-id-type="pmid">20926784</pub-id></element-citation></ref><ref id="B62"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voon</surname><given-names>V</given-names></name><name><surname>Pessiglione</surname><given-names>M</given-names></name><name><surname>Brezing</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors</article-title><source><italic>Neuron</italic></source><year>2010</year><volume>65</volume><issue>1</issue><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="other">2-s2.0-73549113279</pub-id><pub-id pub-id-type="pmid">20152119</pub-id></element-citation></ref><ref id="B63"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>A</given-names></name><name><surname>Ambermoon</surname><given-names>P</given-names></name><name><surname>Hall</surname><given-names>WD</given-names></name></person-group><article-title>Drug-induced impulse control disorders: a prospectus for neuroethical analysis</article-title><source><italic>Neuroethics</italic></source><year>2011</year><volume>4</volume><issue>2</issue><fpage>91</fpage><lpage>102</lpage><pub-id pub-id-type="other">2-s2.0-79960461091</pub-id></element-citation></ref><ref id="B64"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamikonyan</surname><given-names>E</given-names></name><name><surname>Siderowf</surname><given-names>AD</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Long-term follow-up of impulse control disorders in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2008</year><volume>23</volume><issue>1</issue><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="other">2-s2.0-39549108128</pub-id><pub-id pub-id-type="pmid">17960796</pub-id></element-citation></ref><ref id="B65"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Pillon</surname><given-names>B</given-names></name></person-group><article-title>Cognitive deficits in Parkinson’s disease</article-title><source><italic>Journal of Neurology</italic></source><year>1997</year><volume>244</volume><issue>1</issue><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="other">2-s2.0-0031060220</pub-id><pub-id pub-id-type="pmid">9007738</pub-id></element-citation></ref><ref id="B66"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Zaccai</surname><given-names>J</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name></person-group><article-title>A systematic review of prevalence studies of dementia in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2005</year><volume>20</volume><issue>10</issue><fpage>1255</fpage><lpage>1263</lpage><pub-id pub-id-type="other">2-s2.0-27844469751</pub-id><pub-id pub-id-type="pmid">16041803</pub-id></element-citation></ref><ref id="B67"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Lau</surname><given-names>LML</given-names></name><name><surname>Schipper</surname><given-names>CMA</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Koudstaal</surname><given-names>PJ</given-names></name><name><surname>Breteler</surname><given-names>MMB</given-names></name></person-group><article-title>Prognosis of parkinson disease. Risk of dementia and mortality: the rotterdam study</article-title><source><italic>Archives of Neurology</italic></source><year>2005</year><volume>62</volume><issue>8</issue><fpage>1265</fpage><lpage>1269</lpage><pub-id pub-id-type="other">2-s2.0-23844437947</pub-id><pub-id pub-id-type="pmid">16087767</pub-id></element-citation></ref><ref id="B68"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>TA</given-names></name><name><surname>Ross</surname><given-names>HF</given-names></name><name><surname>Musa</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease</article-title><source><italic>Neurology</italic></source><year>2000</year><volume>54</volume><issue>8</issue><fpage>1596</fpage><lpage>1602</lpage><pub-id pub-id-type="other">2-s2.0-0034050423</pub-id><pub-id pub-id-type="pmid">10762499</pub-id></element-citation></ref><ref id="B69"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Andersen</surname><given-names>K</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>Lolk</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>H</given-names></name><name><surname>Kragh-Sørensen</surname><given-names>P</given-names></name></person-group><article-title>Risk of dementia in Parkinson’s disease: a community-based, prospective study</article-title><source><italic>Neurology</italic></source><year>2001</year><volume>56</volume><issue>6</issue><fpage>730</fpage><lpage>736</lpage><pub-id pub-id-type="other">2-s2.0-0035957311</pub-id><pub-id pub-id-type="pmid">11274306</pub-id></element-citation></ref><ref id="B70"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohnen</surname><given-names>NI</given-names></name><name><surname>Kaufer</surname><given-names>DI</given-names></name><name><surname>Ivanco</surname><given-names>LS</given-names></name><etal></etal></person-group><article-title>Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study</article-title><source><italic>Archives of Neurology</italic></source><year>2003</year><volume>60</volume><issue>12</issue><fpage>1745</fpage><lpage>1748</lpage><pub-id pub-id-type="other">2-s2.0-0347385143</pub-id><pub-id pub-id-type="pmid">14676050</pub-id></element-citation></ref><ref id="B71"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Mosimann</surname><given-names>UP</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name></person-group><article-title>Role of cholinesterase inhibitors in Parkinson’s disease and dementia with Lewy bodies</article-title><source><italic>Journal of Geriatric Psychiatry and Neurology</italic></source><year>2004</year><volume>17</volume><issue>3</issue><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="other">2-s2.0-4344613595</pub-id><pub-id pub-id-type="pmid">15312280</pub-id></element-citation></ref><ref id="B72"><label>71</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JL</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Wolters</surname><given-names>EC</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name></person-group><article-title>Psychosis in basal ganglia disorders</article-title><source><italic>Mental Dysfunction in Parkinson’s Disease</italic></source><year>1993</year><publisher-loc>Amsterdam, The Netherlands</publisher-loc><publisher-name>Vriije Universiteit</publisher-name></element-citation></ref><ref id="B73"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsaa</surname><given-names>EB</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>Wentzel-Larsen</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>A 12-year population-based study of psychosis in Parkinson disease</article-title><source><italic>Archives of Neurology</italic></source><year>2010</year><volume>67</volume><issue>8</issue><fpage>996</fpage><lpage>1001</lpage><pub-id pub-id-type="other">2-s2.0-77955460535</pub-id><pub-id pub-id-type="pmid">20697051</pub-id></element-citation></ref><ref id="B74"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fénelon</surname><given-names>G</given-names></name><name><surname>Mahieux</surname><given-names>F</given-names></name><name><surname>Huon</surname><given-names>R</given-names></name><name><surname>Ziégler</surname><given-names>M</given-names></name></person-group><article-title>Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors</article-title><source><italic>Brain</italic></source><year>2000</year><volume>123</volume><issue>4</issue><fpage>733</fpage><lpage>745</lpage><pub-id pub-id-type="other">2-s2.0-0342424352</pub-id><pub-id pub-id-type="pmid">10734005</pub-id></element-citation></ref><ref id="B75"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenelon</surname><given-names>G</given-names></name><name><surname>Alves</surname><given-names>G</given-names></name></person-group><article-title>Epidemiology of psychosis in Parkinson’s disease</article-title><source><italic>Journal of the Neurological Sciences</italic></source><year>2010</year><volume>289</volume><issue>1-2</issue><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">19740486</pub-id></element-citation></ref><ref id="B76"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diederich</surname><given-names>NJ</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Pappert</surname><given-names>EJ</given-names></name><name><surname>Leurgans</surname><given-names>S</given-names></name><name><surname>Piery</surname><given-names>V</given-names></name></person-group><article-title>Poor visual discrimination and visual hallucinations in Parkinson’s disease</article-title><source><italic>Clinical Neuropharmacology</italic></source><year>1998</year><volume>21</volume><issue>5</issue><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="other">2-s2.0-0031784089</pub-id><pub-id pub-id-type="pmid">9789709</pub-id></element-citation></ref><ref id="B77"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnulf</surname><given-names>I</given-names></name><name><surname>Bonnet</surname><given-names>AM</given-names></name><name><surname>Damier</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis</article-title><source><italic>Neurology</italic></source><year>2000</year><volume>55</volume><issue>2</issue><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="other">2-s2.0-0033854621</pub-id><pub-id pub-id-type="pmid">10908906</pub-id></element-citation></ref><ref id="B78"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Factor</surname><given-names>SA</given-names></name><name><surname>Feustel</surname><given-names>PJ</given-names></name><name><surname>Friedman</surname><given-names>JH</given-names></name><etal></etal></person-group><article-title>Longitudinal outcome of Parkinson’s disease patients with psychosis</article-title><source><italic>Neurology</italic></source><year>2003</year><volume>60</volume><issue>11</issue><fpage>1756</fpage><lpage>1761</lpage><pub-id pub-id-type="other">2-s2.0-0037777720</pub-id><pub-id pub-id-type="pmid">12796526</pub-id></element-citation></ref><ref id="B79"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>MX</given-names></name><name><surname>Louis</surname><given-names>ED</given-names></name><etal></etal></person-group><article-title>The association of incident dementia with mortality in PD</article-title><source><italic>Neurology</italic></source><year>2002</year><volume>59</volume><issue>11</issue><fpage>1708</fpage><lpage>1713</lpage><pub-id pub-id-type="other">2-s2.0-0037058779</pub-id><pub-id pub-id-type="pmid">12473757</pub-id></element-citation></ref><ref id="B80"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fénelon</surname><given-names>G</given-names></name></person-group><article-title>Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms</article-title><source><italic>CNS Spectrums</italic></source><year>2008</year><volume>13</volume><issue>3</issue><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="other">2-s2.0-42149174316</pub-id></element-citation></ref><ref id="B81"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibarretxe-Bilbao</surname><given-names>N</given-names></name><name><surname>Junque</surname><given-names>C</given-names></name><name><surname>Marti</surname><given-names>MJ</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name></person-group><article-title>Cerebral basis of visual hallucinations in Parkinson’s disease: structural and functional MRI studies</article-title><source><italic>Journal of the Neurological Sciences</italic></source><year>2011</year><volume>310</volume><issue>1</issue><fpage>79</fpage><lpage>81</lpage><pub-id pub-id-type="other">2-s2.0-79959449038</pub-id><pub-id pub-id-type="pmid">21705027</pub-id></element-citation></ref><ref id="B82"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramírez-Ruiz</surname><given-names>B</given-names></name><name><surname>Martí</surname><given-names>MJ</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Longitudinal evaluation of cerebral morphological changes in Parkinson’s disease with and without dementia</article-title><source><italic>Journal of Neurology</italic></source><year>2005</year><volume>252</volume><issue>11</issue><fpage>1345</fpage><lpage>1352</lpage><pub-id pub-id-type="other">2-s2.0-25144513700</pub-id><pub-id pub-id-type="pmid">15995795</pub-id></element-citation></ref><ref id="B83"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study</article-title><source><italic>Lancet Neurology</italic></source><year>2005</year><volume>4</volume><issue>10</issue><fpage>605</fpage><lpage>610</lpage><pub-id pub-id-type="other">2-s2.0-24944451475</pub-id><pub-id pub-id-type="pmid">16168928</pub-id></element-citation></ref><ref id="B84"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>JH</given-names></name></person-group><article-title>Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease</article-title><source><italic>New England Journal of Medicine</italic></source><year>1999</year><volume>340</volume><issue>10</issue><fpage>757</fpage><lpage>763</lpage><pub-id pub-id-type="other">2-s2.0-0033545542</pub-id><pub-id pub-id-type="pmid">10072410</pub-id></element-citation></ref><ref id="B85"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koller</surname><given-names>WC</given-names></name></person-group><article-title>Sensory symptoms in Parkinson’s disease</article-title><source><italic>Neurology</italic></source><year>1984</year><volume>34</volume><issue>7</issue><fpage>957</fpage><lpage>959</lpage><pub-id pub-id-type="other">2-s2.0-0021239498</pub-id><pub-id pub-id-type="pmid">6539873</pub-id></element-citation></ref><ref id="B86"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MA</given-names></name><name><surname>Walker</surname><given-names>RW</given-names></name><name><surname>Hildreth</surname><given-names>TJ</given-names></name><name><surname>Prentice</surname><given-names>WM</given-names></name></person-group><article-title>A survey of pain in idiopathic Parkinson’s disease</article-title><source><italic>Journal of Pain and Symptom Management</italic></source><year>2006</year><volume>32</volume><issue>5</issue><fpage>462</fpage><lpage>469</lpage><pub-id pub-id-type="other">2-s2.0-33750502034</pub-id><pub-id pub-id-type="pmid">17085272</pub-id></element-citation></ref><ref id="B87"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Defazio</surname><given-names>G</given-names></name><name><surname>Berardelli</surname><given-names>A</given-names></name><name><surname>Fabbrini</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study</article-title><source><italic>Archives of Neurology</italic></source><year>2008</year><volume>65</volume><issue>9</issue><fpage>1191</fpage><lpage>1194</lpage><pub-id pub-id-type="other">2-s2.0-51649116697</pub-id><pub-id pub-id-type="pmid">18779422</pub-id></element-citation></ref><ref id="B88"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nègre-Pagès</surname><given-names>L</given-names></name><name><surname>Regragui</surname><given-names>W</given-names></name><name><surname>Bouhassira</surname><given-names>D</given-names></name><name><surname>Grandjean</surname><given-names>H</given-names></name><name><surname>Rascol</surname><given-names>O</given-names></name></person-group><article-title>Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey</article-title><source><italic>Movement Disorders</italic></source><year>2008</year><volume>23</volume><issue>10</issue><fpage>1361</fpage><lpage>1369</lpage><pub-id pub-id-type="other">2-s2.0-51849150780</pub-id><pub-id pub-id-type="pmid">18546344</pub-id></element-citation></ref><ref id="B89"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>RS</given-names></name><name><surname>Garron</surname><given-names>DC</given-names></name></person-group><article-title>Pain in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>1986</year><volume>1</volume><fpage>45</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">3504231</pub-id></element-citation></ref><ref id="B92"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>B</given-names></name></person-group><article-title>Pain in Parkinson’s disease</article-title><source><italic>Clinical Neuroscience</italic></source><year>1998</year><volume>5</volume><issue>2</issue><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="other">2-s2.0-0032470588</pub-id><pub-id pub-id-type="pmid">10785830</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>AD</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name></person-group><article-title>Pain in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2012</year><volume>27</volume><issue>4</issue><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">21953990</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beiske</surname><given-names>AG</given-names></name><name><surname>Loge</surname><given-names>JH</given-names></name><name><surname>Rønningen</surname><given-names>A</given-names></name><name><surname>Svensson</surname><given-names>E</given-names></name></person-group><article-title>Pain in Parkinson’s disease: prevalence and characteristics</article-title><source><italic>Pain</italic></source><year>2009</year><volume>141</volume><issue>1-2</issue><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="other">2-s2.0-58149198613</pub-id><pub-id pub-id-type="pmid">19100686</pub-id></element-citation></ref><ref id="B93"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djaldetti</surname><given-names>R</given-names></name><name><surname>Shifrin</surname><given-names>A</given-names></name><name><surname>Rogowski</surname><given-names>Z</given-names></name><name><surname>Sprecher</surname><given-names>E</given-names></name><name><surname>Melamed</surname><given-names>E</given-names></name><name><surname>Yarnitsky</surname><given-names>D</given-names></name></person-group><article-title>Quantitative measurement of pain sensation in patients with Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2004</year><volume>62</volume><issue>12</issue><fpage>2171</fpage><lpage>2175</lpage><pub-id pub-id-type="other">2-s2.0-2942711637</pub-id><pub-id pub-id-type="pmid">15210877</pub-id></element-citation></ref><ref id="B94"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brefel-Courbon</surname><given-names>C</given-names></name><name><surname>Payoux</surname><given-names>P</given-names></name><name><surname>Thalamas</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Effects of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study</article-title><source><italic>Movement Disorders</italic></source><year>2005</year><volume>20</volume><issue>12</issue><fpage>1557</fpage><lpage>1563</lpage><pub-id pub-id-type="other">2-s2.0-33644966535</pub-id><pub-id pub-id-type="pmid">16078219</pub-id></element-citation></ref><ref id="B95"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavreysen</surname><given-names>H</given-names></name><name><surname>Dautzenberg</surname><given-names>FM</given-names></name></person-group><article-title>Therapeutic potential of group III metabotropic glutamate receptors</article-title><source><italic>Current Medicinal Chemistry</italic></source><year>2008</year><volume>15</volume><issue>7</issue><fpage>671</fpage><lpage>684</lpage><pub-id pub-id-type="other">2-s2.0-42049118695</pub-id><pub-id pub-id-type="pmid">18336281</pub-id></element-citation></ref><ref id="B96"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djaldetti</surname><given-names>R</given-names></name><name><surname>Yust-Katz</surname><given-names>S</given-names></name><name><surname>Kolianov</surname><given-names>V</given-names></name><name><surname>Melamed</surname><given-names>E</given-names></name><name><surname>Dabby</surname><given-names>R</given-names></name></person-group><article-title>The effect of duloxetine on primary pain symptoms in Parkinson disease</article-title><source><italic>Clinical Neuropharmacology</italic></source><year>2007</year><volume>30</volume><issue>4</issue><fpage>201</fpage><lpage>205</lpage><pub-id pub-id-type="other">2-s2.0-34548460736</pub-id><pub-id pub-id-type="pmid">17762316</pub-id></element-citation></ref><ref id="B97"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barone</surname><given-names>P</given-names></name><name><surname>Antonini</surname><given-names>A</given-names></name><name><surname>Colossimo</surname><given-names>C</given-names></name><name><surname>Marconi</surname><given-names>R</given-names></name></person-group><article-title>The PRIAMO Study: a multicenter assessment of non motor symptoms and their impact on quality of life in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2009</year><volume>24</volume><issue>11</issue><fpage>1641</fpage><lpage>1649</lpage><pub-id pub-id-type="pmid">19514014</pub-id></element-citation></ref><ref id="B98"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnulf</surname><given-names>I</given-names></name><name><surname>Konofal</surname><given-names>E</given-names></name><name><surname>Merino-Andreu</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Parkinson’s disease and sleepiness: an integral part of PD</article-title><source><italic>Neurology</italic></source><year>2002</year><volume>58</volume><issue>7</issue><fpage>1019</fpage><lpage>1024</lpage><pub-id pub-id-type="other">2-s2.0-0037046219</pub-id><pub-id pub-id-type="pmid">11940685</pub-id></element-citation></ref><ref id="B99"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Borreguero</surname><given-names>D</given-names></name><name><surname>Odin</surname><given-names>P</given-names></name><name><surname>Serrano</surname><given-names>C</given-names></name></person-group><article-title>Restless legs syndrome and PD: a review of the evidence for a possible association</article-title><source><italic>Neurology</italic></source><year>2003</year><volume>61</volume><issue>6, supplement 3</issue><fpage>S49</fpage><lpage>S55</lpage><pub-id pub-id-type="other">2-s2.0-0141632710</pub-id><pub-id pub-id-type="pmid">14504380</pub-id></element-citation></ref><ref id="B100"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnulf</surname><given-names>I</given-names></name><name><surname>Leu</surname><given-names>S</given-names></name><name><surname>Oudiette</surname><given-names>D</given-names></name></person-group><article-title>Abnormal sleep and sleepiness in Parkinson’s disease</article-title><source><italic>Current Opinion in Neurology</italic></source><year>2008</year><volume>21</volume><issue>4</issue><fpage>472</fpage><lpage>477</lpage><pub-id pub-id-type="other">2-s2.0-52049110763</pub-id><pub-id pub-id-type="pmid">18607209</pub-id></element-citation></ref><ref id="B101"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>Lomeña</surname><given-names>F</given-names></name><name><surname>Stockner</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study</article-title><source><italic>The Lancet Neurology</italic></source><year>2010</year><volume>9</volume><issue>11</issue><fpage>1070</fpage><lpage>1077</lpage><pub-id pub-id-type="other">2-s2.0-77957970097</pub-id></element-citation></ref><ref id="B102"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>PK</given-names></name><name><surname>Calne</surname><given-names>S</given-names></name><name><surname>Samii</surname><given-names>A</given-names></name><name><surname>Fleming</surname><given-names>JAE</given-names></name></person-group><article-title>A review of normal sleep and its disturbances in Parkinson’s disease</article-title><source><italic>Parkinsonism and Related Disorders</italic></source><year>1999</year><volume>5</volume><issue>1-2</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="other">2-s2.0-0032991247</pub-id><pub-id pub-id-type="pmid">18591114</pub-id></element-citation></ref><ref id="B103"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tandberg</surname><given-names>E</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>Karlsen</surname><given-names>K</given-names></name></person-group><article-title>Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study</article-title><source><italic>Movement Disorders</italic></source><year>1999</year><volume>14</volume><fpage>922</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">10584665</pub-id></element-citation></ref><ref id="B104"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diederich</surname><given-names>NJ</given-names></name><name><surname>McIntyre</surname><given-names>DJ</given-names></name></person-group><article-title>Sleep disorders in Parkinson’s disease: many causes, few therapeutic options</article-title><source><italic>Journal of the Neurological Sciences</italic></source><year>2011</year><volume>314</volume><issue>1-2</issue><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">22118862</pub-id></element-citation></ref><ref id="B105"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barone</surname><given-names>P</given-names></name><name><surname>Amboni</surname><given-names>M</given-names></name><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Bonavita</surname><given-names>V</given-names></name></person-group><article-title>Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson’s disease</article-title><source><italic>Neurology</italic></source><year>2004</year><volume>63</volume><issue>8</issue><fpage>S35</fpage><lpage>S38</lpage><pub-id pub-id-type="other">2-s2.0-7044251840</pub-id><pub-id pub-id-type="pmid">15505142</pub-id></element-citation></ref><ref id="B106"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Post</surname><given-names>KK</given-names></name><name><surname>Singer</surname><given-names>C</given-names></name><name><surname>Papapetropoulos</surname><given-names>S</given-names></name></person-group><article-title>Cardiac denervation and dysautonomia in Parkinson’s disease: a review of screening techniques</article-title><source><italic>Parkinsonism and Related Disorders</italic></source><year>2008</year><volume>14</volume><issue>7</issue><fpage>524</fpage><lpage>531</lpage><pub-id pub-id-type="other">2-s2.0-53849110251</pub-id><pub-id pub-id-type="pmid">18486523</pub-id></element-citation></ref><ref id="B107"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Marinus</surname><given-names>J</given-names></name><name><surname>Stiggelbout</surname><given-names>AM</given-names></name><name><surname>van Hilten</surname><given-names>JJ</given-names></name></person-group><article-title>Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT</article-title><source><italic>Movement Disorders</italic></source><year>2004</year><volume>19</volume><issue>11</issue><fpage>1306</fpage><lpage>1312</lpage><pub-id pub-id-type="other">2-s2.0-8844248645</pub-id><pub-id pub-id-type="pmid">15390007</pub-id></element-citation></ref><ref id="B108"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakakibara</surname><given-names>R</given-names></name><name><surname>Uchiyama</surname><given-names>T</given-names></name><name><surname>Yamanishi</surname><given-names>T</given-names></name><name><surname>Kishi</surname><given-names>M</given-names></name></person-group><article-title>Genitourinary dysfunction in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2010</year><volume>25</volume><issue>1</issue><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="other">2-s2.0-75749156928</pub-id><pub-id pub-id-type="pmid">20077468</pub-id></element-citation></ref><ref id="B109"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakakibara</surname><given-names>R</given-names></name><name><surname>Shinotoh</surname><given-names>H</given-names></name><name><surname>Uchiyama</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease</article-title><source><italic>Autonomic Neuroscience</italic></source><year>2001</year><volume>92</volume><issue>1-2</issue><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type="other">2-s2.0-0035903990</pub-id><pub-id pub-id-type="pmid">11570707</pub-id></element-citation></ref><ref id="B110"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Schwarzschild</surname><given-names>MA</given-names></name><etal></etal></person-group><article-title>Erectile function and risk of Parkinson’s disease</article-title><source><italic>American Journal of Epidemiology</italic></source><year>2007</year><volume>166</volume><issue>12</issue><fpage>1446</fpage><lpage>1450</lpage><pub-id pub-id-type="other">2-s2.0-36749033706</pub-id><pub-id pub-id-type="pmid">17875583</pub-id></element-citation></ref><ref id="B111"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahrmann</surname><given-names>H</given-names></name><name><surname>Cortelli</surname><given-names>P</given-names></name><name><surname>Hilz</surname><given-names>M</given-names></name><name><surname>Mathias</surname><given-names>CJ</given-names></name><name><surname>Struhal</surname><given-names>W</given-names></name><name><surname>Tassinari</surname><given-names>M</given-names></name></person-group><article-title>EFNS guidelines on the diagnosis and management of orthostatic hypotension</article-title><source><italic>European Journal of Neurology</italic></source><year>2006</year><volume>13</volume><issue>9</issue><fpage>930</fpage><lpage>936</lpage><pub-id pub-id-type="other">2-s2.0-33747865174</pub-id><pub-id pub-id-type="pmid">16930356</pub-id></element-citation></ref><ref id="B112"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senard</surname><given-names>JM</given-names></name><name><surname>Pathak</surname><given-names>A</given-names></name></person-group><article-title xml:lang="fr">Neurogenic orthostatic hypotension of Parkinson’s disease: what exploration for what treatment?</article-title><source><italic>Revue Neurologique</italic></source><year>2010</year><volume>166</volume><issue>10</issue><fpage>779</fpage><lpage>784</lpage><pub-id pub-id-type="other">2-s2.0-77957235662</pub-id><pub-id pub-id-type="pmid">20817229</pub-id></element-citation></ref><ref id="B113"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senard</surname><given-names>JM</given-names></name><name><surname>Raï</surname><given-names>S</given-names></name><name><surname>Lapeyre-Mestre</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Prevalence of orthostatic hypotension in Parkinson’s disease</article-title><source><italic>Journal of Neurology Neurosurgery and Psychiatry</italic></source><year>1997</year><volume>63</volume><issue>5</issue><fpage>584</fpage><lpage>589</lpage><pub-id pub-id-type="other">2-s2.0-0030669957</pub-id></element-citation></ref><ref id="B114"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senard</surname><given-names>JM</given-names></name><name><surname>Valet</surname><given-names>P</given-names></name><name><surname>Durrieu</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension</article-title><source><italic>European Journal of Clinical Investigation</italic></source><year>1990</year><volume>20</volume><issue>6</issue><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="other">2-s2.0-0025601999</pub-id><pub-id pub-id-type="pmid">1964123</pub-id></element-citation></ref><ref id="B115"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senard</surname><given-names>JM</given-names></name><name><surname>Brefel-Courbon</surname><given-names>C</given-names></name><name><surname>Rascol</surname><given-names>O</given-names></name><name><surname>Montastruc</surname><given-names>JL</given-names></name></person-group><article-title>Orthostatic hypotension in patients with Parkinson’s disease: pathophysiology and management</article-title><source><italic>Drugs and Aging</italic></source><year>2001</year><volume>18</volume><issue>7</issue><fpage>495</fpage><lpage>505</lpage><pub-id pub-id-type="other">2-s2.0-0034913776</pub-id><pub-id pub-id-type="pmid">11482743</pub-id></element-citation></ref><ref id="B116"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allcock</surname><given-names>LM</given-names></name><name><surname>Kenny</surname><given-names>RA</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name></person-group><article-title>Clinical phenotype of subjects with Parkinson’s disease orthostatic hypotension: autonomic symptom and demographic comparison</article-title><source><italic>Movement Disorders</italic></source><year>2006</year><volume>21</volume><issue>11</issue><fpage>1851</fpage><lpage>1855</lpage><pub-id pub-id-type="other">2-s2.0-33845192156</pub-id><pub-id pub-id-type="pmid">16958096</pub-id></element-citation></ref><ref id="B117"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savica</surname><given-names>R</given-names></name><name><surname>Carlin</surname><given-names>JM</given-names></name><name><surname>Grossardt</surname><given-names>BR</given-names></name><etal></etal></person-group><article-title>Medical records documentation of constipation preceding Parkinson disease: a case-control study</article-title><source><italic>Neurology</italic></source><year>2009</year><volume>73</volume><issue>21</issue><fpage>1752</fpage><lpage>1758</lpage><pub-id pub-id-type="other">2-s2.0-73349092154</pub-id><pub-id pub-id-type="pmid">19933976</pub-id></element-citation></ref><ref id="B118"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>LR</given-names></name><etal></etal></person-group><article-title>Frequency of bowel movements and the future risk of Parkinson’s disease</article-title><source><italic>Neurology</italic></source><year>2001</year><volume>57</volume><issue>3</issue><fpage>456</fpage><lpage>462</lpage><pub-id pub-id-type="other">2-s2.0-0035859865</pub-id><pub-id pub-id-type="pmid">11502913</pub-id></element-citation></ref><ref id="B119"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakakibara</surname><given-names>R</given-names></name><name><surname>Uchiyama</surname><given-names>T</given-names></name><name><surname>Yamanishi</surname><given-names>T</given-names></name><name><surname>Shirai</surname><given-names>K</given-names></name><name><surname>Hattori</surname><given-names>T</given-names></name></person-group><article-title>Bladder and bowel dysfunction in Parkinson’s disease</article-title><source><italic>Journal of Neural Transmission</italic></source><year>2008</year><volume>115</volume><issue>3</issue><fpage>443</fpage><lpage>460</lpage><pub-id pub-id-type="other">2-s2.0-49949152130</pub-id><pub-id pub-id-type="pmid">18327532</pub-id></element-citation></ref><ref id="B120"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stacy</surname><given-names>M</given-names></name><name><surname>Hauser</surname><given-names>R</given-names></name></person-group><article-title>Development of a patient questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson’s disease</article-title><source><italic>Journal of Neural Transmission</italic></source><year>2007</year><volume>114</volume><issue>2</issue><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="other">2-s2.0-33846425415</pub-id><pub-id pub-id-type="pmid">16897594</pub-id></element-citation></ref><ref id="B121"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayulkem</surname><given-names>K</given-names></name><name><surname>Lopez</surname><given-names>G</given-names></name></person-group><article-title>Non motor fluctuatons in Parkinson’s disease: clinical spectrum and classification</article-title><source><italic>Journal of the Neurological Sciences</italic></source><year>2010</year><volume>289</volume><fpage>89</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">19747695</pub-id></element-citation></ref><ref id="B122"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>SH</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name></person-group><article-title>Motor and non-motor fluctuations</article-title><source><italic>Handbook of Clinical Neurology</italic></source><year>2007</year><volume>84</volume><fpage>157</fpage><lpage>184</lpage><pub-id pub-id-type="other">2-s2.0-67649327177</pub-id><pub-id pub-id-type="pmid">18808948</pub-id></element-citation></ref><ref id="B123"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>DE</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name></person-group><article-title>The spectrum of levodopa-related fluctuations in Parkinson’s disease</article-title><source><italic>Neurology</italic></source><year>1993</year><volume>43</volume><issue>8</issue><fpage>1459</fpage><lpage>1464</lpage><pub-id pub-id-type="other">2-s2.0-0027328494</pub-id><pub-id pub-id-type="pmid">8350996</pub-id></element-citation></ref><ref id="B124"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>KR</given-names></name><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><name><surname>Schapira</surname><given-names>AHV</given-names></name><etal></etal></person-group><article-title>International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study</article-title><source><italic>Movement Disorders</italic></source><year>2006</year><volume>21</volume><issue>7</issue><fpage>916</fpage><lpage>923</lpage><pub-id pub-id-type="other">2-s2.0-33746889002</pub-id><pub-id pub-id-type="pmid">16547944</pub-id></element-citation></ref><ref id="B125"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><name><surname>Rodriguez-Blazquez</surname><given-names>C</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2009</year><volume>73</volume><issue>19</issue><fpage>1584</fpage><lpage>1591</lpage><pub-id pub-id-type="other">2-s2.0-72049092374</pub-id><pub-id pub-id-type="pmid">19901251</pub-id></element-citation></ref><ref id="B126"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>DA</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Schrag</surname><given-names>A</given-names></name></person-group><article-title>What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them?</article-title><source><italic>Movement Disorders</italic></source><year>2010</year><volume>25</volume><issue>15</issue><fpage>2493</fpage><lpage>2500</lpage><pub-id pub-id-type="other">2-s2.0-78349236177</pub-id><pub-id pub-id-type="pmid">20922807</pub-id></element-citation></ref><ref id="B127"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>KR</given-names></name><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>RG</given-names></name><etal></etal></person-group><article-title>The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study</article-title><source><italic>Movement Disorders</italic></source><year>2007</year><volume>22</volume><issue>13</issue><fpage>1901</fpage><lpage>1911</lpage><pub-id pub-id-type="other">2-s2.0-36248998208</pub-id><pub-id pub-id-type="pmid">17674410</pub-id></element-citation></ref><ref id="B128"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marinus</surname><given-names>J</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Stiggelbout</surname><given-names>AM</given-names></name><etal></etal></person-group><article-title>Activity-based diary for Parkinson’s disease</article-title><source><italic>Clinical Neuropharmacology</italic></source><year>2002</year><volume>25</volume><issue>1</issue><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="other">2-s2.0-0036179453</pub-id><pub-id pub-id-type="pmid">11852296</pub-id></element-citation></ref><ref id="B129"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Marinus</surname><given-names>J</given-names></name><name><surname>Stiggelbout</surname><given-names>AM</given-names></name><name><surname>van Hilten</surname><given-names>JJ</given-names></name></person-group><article-title>Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT</article-title><source><italic>Movement Disorders</italic></source><year>2004</year><volume>19</volume><issue>11</issue><fpage>1306</fpage><lpage>1312</lpage><pub-id pub-id-type="other">2-s2.0-8844248645</pub-id><pub-id pub-id-type="pmid">15390007</pub-id></element-citation></ref><ref id="B130"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbaan</surname><given-names>D</given-names></name><name><surname>Marinus</surname><given-names>J</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Van Rooden</surname><given-names>SM</given-names></name><name><surname>Stiggelbout</surname><given-names>AM</given-names></name><name><surname>Van Hilten</surname><given-names>JJ</given-names></name></person-group><article-title>Patient-reported autonomic symptoms in Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2007</year><volume>69</volume><issue>4</issue><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="other">2-s2.0-34547643553</pub-id><pub-id pub-id-type="pmid">17646625</pub-id></element-citation></ref><ref id="B131"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rendas-Baum</surname><given-names>R</given-names></name><name><surname>Buck</surname><given-names>PO</given-names></name><name><surname>White</surname><given-names>MK</given-names></name><name><surname>Castelli-Haley</surname><given-names>J</given-names></name></person-group><article-title>Psychometric validation of the revised SCOPA-Diary Card: expanding the measurement of non-motor symptoms in Parkinson’s disease</article-title><source><italic>Health and Quality of Life Outcomes</italic></source><year>2011</year><volume>9, article 69</volume></element-citation></ref><ref id="B132"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Tilley</surname><given-names>BC</given-names></name><name><surname>Shaftman</surname><given-names>SR</given-names></name><etal></etal></person-group><article-title>Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results</article-title><source><italic>Movement Disorders</italic></source><year>2008</year><volume>23</volume><issue>15</issue><fpage>2129</fpage><lpage>2170</lpage><pub-id pub-id-type="other">2-s2.0-61449165975</pub-id><pub-id pub-id-type="pmid">19025984</pub-id></element-citation></ref><ref id="B133"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>DA</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Stebbins</surname><given-names>G</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Schrag</surname><given-names>A</given-names></name></person-group><article-title>Validation of the MDS-UPDRS Part 1 for nonmotor symptoms in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2012</year><volume>27</volume><issue>1</issue><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">21915909</pub-id></element-citation></ref><ref id="B134"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleiner-Fisman</surname><given-names>G</given-names></name><name><surname>Martine</surname><given-names>R</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Stern</surname><given-names>MB</given-names></name></person-group><article-title>Development of a non-motor fluctuation assessment instrument for Parkinson’s disease</article-title><source><italic>Parkinsonism & Related Disorders</italic></source><year>2011</year><volume>2011</volume><fpage>13 pages</fpage><pub-id pub-id-type="publisher-id">292719</pub-id></element-citation></ref><ref id="B135"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Högl</surname><given-names>B</given-names></name><name><surname>Arnulf</surname><given-names>I</given-names></name><name><surname>Comella</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Scales to assess sleep impairment in Parkinson’s disease: critique and recommendations</article-title><source><italic>Movement Disorders</italic></source><year>2010</year><volume>25</volume><issue>16</issue><fpage>2704</fpage><lpage>2716</lpage><pub-id pub-id-type="other">2-s2.0-78650195329</pub-id><pub-id pub-id-type="pmid">20931631</pub-id></element-citation></ref><ref id="B136"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Hoops</surname><given-names>S</given-names></name><name><surname>Shea</surname><given-names>JA</given-names></name><etal></etal></person-group><article-title>Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2009</year><volume>24</volume><issue>10</issue><fpage>1461</fpage><lpage>1467</lpage><pub-id pub-id-type="other">2-s2.0-69849087869</pub-id><pub-id pub-id-type="pmid">19452562</pub-id></element-citation></ref><ref id="B138"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>AE</given-names></name></person-group><article-title>A critical appraisal of the premotor symptoms of Parkinson’s disease: potential usefulness in early diagnosis and design of neuroprotective trials</article-title><source><italic>Movement Disorders</italic></source><year>2011</year><volume>26</volume><issue>5</issue><fpage>775</fpage><lpage>783</lpage><pub-id pub-id-type="other">2-s2.0-79955112282</pub-id><pub-id pub-id-type="pmid">21484865</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Gaig</surname><given-names>C</given-names></name><name><surname>Santamaría</surname><given-names>J</given-names></name><name><surname>Compta</surname><given-names>Y</given-names></name></person-group><article-title>Diagnosis and the premotor phase of Parkinson disease</article-title><source><italic>Neurology</italic></source><year>2009</year><volume>72</volume><issue>7</issue><fpage>S12</fpage><lpage>S20</lpage><pub-id pub-id-type="other">2-s2.0-61949235512</pub-id><pub-id pub-id-type="pmid">19221308</pub-id></element-citation></ref><ref id="B139"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponsen</surname><given-names>MM</given-names></name><name><surname>Stoffers</surname><given-names>D</given-names></name><name><surname>Booij</surname><given-names>J</given-names></name><name><surname>Van Eck-Smit</surname><given-names>BLF</given-names></name><name><surname>Wolters</surname><given-names>EC</given-names></name><name><surname>Berendse</surname><given-names>HW</given-names></name></person-group><article-title>Idiopathic hyposmia as a preclinical sign of Parkinson’s disease</article-title><source><italic>Annals of Neurology</italic></source><year>2004</year><volume>56</volume><issue>2</issue><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="other">2-s2.0-3843078591</pub-id><pub-id pub-id-type="pmid">15293269</pub-id></element-citation></ref><ref id="B140"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>GW</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><name><surname>Abbott</surname><given-names>RD</given-names></name><etal></etal></person-group><article-title>Association of olfactory dysfunction with risk for future Parkinson’s disease</article-title><source><italic>Annals of Neurology</italic></source><year>2008</year><volume>63</volume><issue>2</issue><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="other">2-s2.0-40449083312</pub-id><pub-id pub-id-type="pmid">18067173</pub-id></element-citation></ref><ref id="B142"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Ross</surname><given-names>GW</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Bowel movement frequency in late-life and incidental lewy bodies</article-title><source><italic>Movement Disorders</italic></source><year>2007</year><volume>22</volume><issue>11</issue><fpage>1581</fpage><lpage>1586</lpage><pub-id pub-id-type="other">2-s2.0-34748826388</pub-id><pub-id pub-id-type="pmid">17523195</pub-id></element-citation></ref><ref id="B143"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Bohl</surname><given-names>JR</given-names></name><name><surname>Müller</surname><given-names>CM</given-names></name><name><surname>Rüb</surname><given-names>U</given-names></name><name><surname>de Vos</surname><given-names>RAI</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name></person-group><article-title>Stanley Fahn lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered</article-title><source><italic>Movement Disorders</italic></source><year>2006</year><volume>21</volume><issue>12</issue><fpage>2042</fpage><lpage>2051</lpage><pub-id pub-id-type="other">2-s2.0-33846419768</pub-id><pub-id pub-id-type="pmid">17078043</pub-id></element-citation></ref><ref id="B144"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebouvier</surname><given-names>T</given-names></name><name><surname>Chaumette</surname><given-names>T</given-names></name><name><surname>Damier</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Pathological lesions in colonic biopsies during Parkinson’s disease</article-title><source><italic>Gut</italic></source><year>2008</year><volume>57</volume><issue>12</issue><fpage>1741</fpage><lpage>1743</lpage><pub-id pub-id-type="other">2-s2.0-56549121613</pub-id><pub-id pub-id-type="pmid">19022934</pub-id></element-citation></ref><ref id="B145"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leentjens</surname><given-names>AFG</given-names></name><name><surname>Van den Akker</surname><given-names>M</given-names></name><name><surname>Metsemakers</surname><given-names>JFM</given-names></name><name><surname>Lousberg</surname><given-names>R</given-names></name><name><surname>Verhey</surname><given-names>FRJ</given-names></name></person-group><article-title>Higher incidence of depression preceding the onset of parkinson’s disease: a register study</article-title><source><italic>Movement Disorders</italic></source><year>2003</year><volume>18</volume><issue>4</issue><fpage>414</fpage><lpage>418</lpage><pub-id pub-id-type="other">2-s2.0-0038747039</pub-id><pub-id pub-id-type="pmid">12671948</pub-id></element-citation></ref><ref id="B146"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tandberg</surname><given-names>E</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>Karlsen</surname><given-names>K</given-names></name></person-group><article-title>A community-based study of sleep disorders in patients with Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>1998</year><volume>13</volume><issue>6</issue><fpage>895</fpage><lpage>899</lpage><pub-id pub-id-type="other">2-s2.0-0031770530</pub-id><pub-id pub-id-type="pmid">9827612</pub-id></element-citation></ref><ref id="B147"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Bhatia</surname><given-names>M</given-names></name><name><surname>Behari</surname><given-names>M</given-names></name></person-group><article-title>Sleep disorders in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2002</year><volume>17</volume><issue>4</issue><fpage>775</fpage><lpage>781</lpage><pub-id pub-id-type="other">2-s2.0-0036654491</pub-id><pub-id pub-id-type="pmid">12210875</pub-id></element-citation></ref><ref id="B148"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Santamaría</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study</article-title><source><italic>Lancet Neurology</italic></source><year>2006</year><volume>5</volume><issue>7</issue><fpage>572</fpage><lpage>577</lpage><pub-id pub-id-type="other">2-s2.0-33744991945</pub-id><pub-id pub-id-type="pmid">16781987</pub-id></element-citation></ref><ref id="B149"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>Lomeña</surname><given-names>F</given-names></name><name><surname>Stockner</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study</article-title><source><italic>The Lancet Neurology</italic></source><year>2010</year><volume>9</volume><issue>11</issue><fpage>1070</fpage><lpage>1077</lpage><pub-id pub-id-type="other">2-s2.0-77957970097</pub-id></element-citation></ref><ref id="B150"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Montplaisir</surname><given-names>J</given-names></name></person-group><article-title>Predicting Parkinson’s disease—why, when, and how?</article-title><source><italic>Parkinsonism and Related Disorders</italic></source><year>2009</year><volume>15</volume><issue>3</issue><fpage>S105</fpage><lpage>S109</lpage><pub-id pub-id-type="other">2-s2.0-71849089217</pub-id><pub-id pub-id-type="pmid">20082967</pub-id></element-citation></ref><ref id="B151"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Rüb</surname><given-names>U</given-names></name><name><surname>De Vos</surname><given-names>RAI</given-names></name><name><surname>Jansen Steur</surname><given-names>ENH</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Staging of brain pathology related to sporadic Parkinson’s disease</article-title><source><italic>Neurobiology of Aging</italic></source><year>2003</year><volume>24</volume><issue>2</issue><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="other">2-s2.0-0037333666</pub-id><pub-id pub-id-type="pmid">12498954</pub-id></element-citation></ref><ref id="B152"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forno</surname><given-names>LS</given-names></name></person-group><article-title>Neuropathology of Parkinson’s disease</article-title><source><italic>Journal of Neuropathology and Experimental Neurology</italic></source><year>1996</year><volume>55</volume><issue>3</issue><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="other">2-s2.0-0029981526</pub-id><pub-id pub-id-type="pmid">8786384</pub-id></element-citation></ref><ref id="B153"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>KR</given-names></name><name><surname>Prieto-Jurcynska</surname><given-names>C</given-names></name><name><surname>Naidu</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire</article-title><source><italic>Movement Disorders</italic></source><year>2010</year><volume>25</volume><issue>6</issue><fpage>704</fpage><lpage>709</lpage><pub-id pub-id-type="other">2-s2.0-77951822093</pub-id><pub-id pub-id-type="pmid">20437539</pub-id></element-citation></ref><ref id="B154"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>LM</given-names></name><name><surname>Taback</surname><given-names>RL</given-names></name><name><surname>Rabinstein</surname><given-names>AA</given-names></name><name><surname>Weiner</surname><given-names>WJ</given-names></name></person-group><article-title>Non-recognition of depression and other non-motor symptoms in Parkinson’s disease</article-title><source><italic>Parkinsonism and Related Disorders</italic></source><year>2002</year><volume>8</volume><issue>3</issue><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="other">2-s2.0-0036131985</pub-id><pub-id pub-id-type="pmid">12039431</pub-id></element-citation></ref><ref id="B155"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><name><surname>Rodriguez-Blazquez</surname><given-names>C</given-names></name><name><surname>Kurtis</surname><given-names>MM</given-names></name><name><surname>Chaudhuri</surname><given-names>KR</given-names></name></person-group><article-title>The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2011</year><volume>26</volume><issue>3</issue><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="other">2-s2.0-79953276342</pub-id><pub-id pub-id-type="pmid">21264941</pub-id></element-citation></ref><ref id="B156"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname><given-names>M</given-names></name><name><surname>Raggi</surname><given-names>A</given-names></name><name><surname>Pagani</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Relationship between disability, quality of life and prevalence of non motor symptoms in Parkinson’s disease</article-title><source><italic>Parkinsonism & Related Disorders</italic></source><year>2012</year><volume>18</volume><issue>1</issue><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">21880537</pub-id></element-citation></ref><ref id="B157"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinnel</surname><given-names>C</given-names></name><name><surname>Hurt</surname><given-names>CS</given-names></name><name><surname>Landau</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>RG</given-names></name><name><surname>Samuel</surname><given-names>M</given-names></name></person-group><article-title>Non-motor versus motor symptoms: how much do they matter to health status in Parkinson’s disease</article-title><source><italic>Movement Disorders</italic></source><year>2011</year><volume>27</volume><issue>2</issue><fpage>236</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">21954027</pub-id></element-citation></ref><ref id="B158"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Van Rooden</surname><given-names>SM</given-names></name><name><surname>Verbaan</surname><given-names>D</given-names></name><name><surname>Marinus</surname><given-names>J</given-names></name><name><surname>Stiggelbout</surname><given-names>AM</given-names></name><name><surname>Van Hilten</surname><given-names>JJ</given-names></name></person-group><article-title>A comprehensive model of health-related quality of life in Parkinson’s disease</article-title><source><italic>Journal of Neurology</italic></source><year>2008</year><volume>255</volume><issue>10</issue><fpage>1580</fpage><lpage>1587</lpage><pub-id pub-id-type="other">2-s2.0-56349168840</pub-id><pub-id pub-id-type="pmid">18821041</pub-id></element-citation></ref><ref id="B159"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zesiewicz</surname><given-names>TA</given-names></name><name><surname>Sullivan</surname><given-names>KL</given-names></name><name><surname>Arnulf</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the quality standards subcommittee of the American academy of neurology</article-title><source><italic>Neurology</italic></source><year>2010</year><volume>74</volume><issue>11</issue><fpage>924</fpage><lpage>931</lpage><pub-id pub-id-type="other">2-s2.0-77950475028</pub-id><pub-id pub-id-type="pmid">20231670</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Major nonmotor symptoms (NMS) in PD (adapted from [<xref ref-type="bibr" rid="B3">3</xref>]).</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">(a) Neuropsychiatric symptoms:</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (1) Depression</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (2) Anxiety</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (3) Apathy</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (4) Hallucinations, delusions, illusions</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (5) Delirium (may be drug induced)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (6) Cognitive impairment (dementia, MCI)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (7) Dopaminergic dysregulation syndrome (usually related to</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> levodopa)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (8) Impulse control disorders (related to dopaminergic drugs).</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(b) Sleep disorders:</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (1) REM sleep behaviour disorder (possible premotor</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> symptoms)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (2) excessive daytime somnolence, narcolepsy type “sleep</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> attack”</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (3) restless legs syndrome, periodic leg movements</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (4) insomnia</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (5) sleep disordered breathing</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (6) non-REM parasomnias (confusional wandering)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(c) Fatigue:</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (1) central fatigue (may be related to dysautonomia)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (2) peripheral fatigue.</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(d) Sensory symptoms:</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (1) pain</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (2) olfactory disturbance</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (3) hyposmia</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (4) functional anosmia</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (5) visual disturbance (blurred vision, diplopia; impaired</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> contrast-sensitivity).</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(e) Autonomic dysfunction:</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (1) bladder dysfunction (urgency, frequency, nocturia)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (2) sexual dysfunction (may be drug-induced)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (3) sweating abnormalities (hyperhydrosis)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (4) orthostatic hypotension.</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(f) Gastrointestinal symptoms:</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (1) dribbling of saliva</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (2) dysphagia</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (3) agueusia</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (4) constipation</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (5) nausea</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (6) vomiting.</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(g) Dopaminergic drug-induced behaviour NMS:</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (1) hallucinations, psychosis, delusions</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (2) dopamine dysregulation syndrome</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (3) impulse control disorders.</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(h) Dopaminergic drug-induced other NMS:</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (1) ankle swelling</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (2) dyspnea</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (3) skin reactions</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (4) subcutaneous nodules</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (5) erythematous</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(i) Nonmotor fluctuations:</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (1) dysautonomia</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (2) cognitive/psychiatric</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (3) sensory/pain</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (4) visual blurring</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(j) Other symptoms:</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (1) weight loss</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (2) weight gain.</td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Classification of pain in PD adapted by [<xref ref-type="bibr" rid="B92">89</xref>].</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">Musculoskeletal: aching, cramping, arthralgic, myalgic sensations in joints, and muscles; may exacerbated by parkinsonian rigidity, stiffness, and immobility, postural abnormalities, and relieved by mobility; may be associated rheumatologic and orthopaedic disease. May fluctuate with medication dosing, and improve with levodopa.</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Dystonic: associated with sustained twisting movements and postures; muscular contractions often very forceful and painful; may fluctuate closely with medication dosing: wearing off dystonia, early morning dystonia, peak-dose dystonia, diphasic dystonia.</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Radicular/Neuropathic: pain in a root or nerve territory, associated with motor or sensory signs of nerve or root entrapment.</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Central or primary pain: burning, tingling, formication, “neuropathic” sensations, often relentless and bizarre in quality, not confined to root or nerve territory; pain may have an autonomic character, with visceral sensations or dyspnea, and vary in parallel with the medication cycle as a non-motor fluctuation; not explained by rigidity, dystonia, musculoskeletal or internal lesion.</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Akathisia: subjective sense of restlessness, often accompanied by urge to move; may fluctuate with medication effect, and improve with levodopa.</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Others types of pain: oral and genital pain; burning mouth or vagina syndrome; may represent a sensory wearing off and may improve with L-dopa.</td><td align="center" rowspan="1" colspan="1"></td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Nonmotor fluctuations in Parkinson's disease (modified from [<xref ref-type="bibr" rid="B122">121</xref>, <xref ref-type="bibr" rid="B123">122</xref>].</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">(1) Neuropsychiatric</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (a) Mood: anxiety, depression, panic attacks, apathy,</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> moaning/screaming, and fatigue</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (b) Psychotic symptoms: visual hallucinations, delusions,</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> paranoia, hypomania/mania, dopamine dysregulation</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> syndrome, euphoria, and agitation</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (c) Cognitive dysfunction</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(2) Autonomic</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (a) Thermoregulation: sweating, facial flushing, pallor,</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> hyperthermia</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (b) Dysphagia, dribbling of saliva, dry mouth, belching,</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> nausea, abdominal bloating discomfort, constipation, and</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> anismus</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (c) Urinary frequency and urgency</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (d) Blood pressure changes, tachycardia</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (e) Dyspnea, cough, stridor</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (f) Peripheral oedema</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (g) Hunger</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (h) Pupillary dilatation</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">(3) Sensory</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (a) Pain</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (b) Internal tremor</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (c) Akathisia, restless legs syndrome</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (d) Sensory dyspnea</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"> (e) Numbness, dysesthesia</td><td align="center" rowspan="1" colspan="1"></td></tr></tbody></table></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Premotor symptoms (adapted from [<xref ref-type="bibr" rid="B138">136</xref>]).</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">Strongest evidence:</td></tr><tr><td align="left" rowspan="1" colspan="1"> (i) Olfactory deficit</td></tr><tr><td align="left" rowspan="1" colspan="1"> (ii) Constipation</td></tr><tr><td align="left" rowspan="1" colspan="1"> (iii) Sleep disorders (EDS, RBD)</td></tr><tr><td align="left" rowspan="1" colspan="1"> (iv) Depression</td></tr><tr><td align="left" rowspan="1" colspan="1">Suggested links:</td></tr><tr><td align="left" rowspan="1" colspan="1"> (i) Other autonomic dysfunction (cardiac…)</td></tr><tr><td align="left" rowspan="1" colspan="1"> (ii) Anxiety</td></tr><tr><td align="left" rowspan="1" colspan="1"> (iii) Visual disturbances</td></tr><tr><td align="left" rowspan="1" colspan="1"> (iv) Cognitive changes</td></tr><tr><td align="left" rowspan="1" colspan="1"> (v) Restless legs syndrome</td></tr><tr><td align="left" rowspan="1" colspan="1"> (vi) Apathy</td></tr><tr><td align="left" rowspan="1" colspan="1"> (vii) Fatigue</td></tr><tr><td align="left" rowspan="1" colspan="1"> (viii) Personality traits</td></tr></tbody></table></table-wrap></floats-group></pmc><affiliations><list><country><li>France</li></country><settlement><li>Paris</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Bonnet, Anne Marie" sort="Bonnet, Anne Marie" uniqKey="Bonnet A" first="Anne" last="Bonnet">Anne Bonnet</name></noRegion><name sortKey="Bonnet, Anne Marie" sort="Bonnet, Anne Marie" uniqKey="Bonnet A" first="Anne" last="Bonnet">Anne Bonnet</name><name sortKey="Bonnet, Anne Marie" sort="Bonnet, Anne Marie" uniqKey="Bonnet A" first="Anne" last="Bonnet">Anne Bonnet</name><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean" last="Corvol">Jean Corvol</name><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean" last="Corvol">Jean Corvol</name><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean" last="Corvol">Jean Corvol</name><name sortKey="Czernecki, Virginie" sort="Czernecki, Virginie" uniqKey="Czernecki V" first="Virginie" last="Czernecki">Virginie Czernecki</name><name sortKey="Czernecki, Virginie" sort="Czernecki, Virginie" uniqKey="Czernecki V" first="Virginie" last="Czernecki">Virginie Czernecki</name><name sortKey="Jutras, Marie France" sort="Jutras, Marie France" uniqKey="Jutras M" first="Marie" last="Jutras">Marie Jutras</name><name sortKey="Jutras, Marie France" sort="Jutras, Marie France" uniqKey="Jutras M" first="Marie" last="Jutras">Marie Jutras</name><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000375 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000375 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:3410355
|texte= Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22888466" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |